TABLE OF CONTENTS
Volume 75, Issue 2 (February 2004)
American Society for Clinical Pharmacology and Therapeutics
MRP2 promoter variants have decreased basal activity in vitro
T. D. Nguyen BS and D. L. Kroetz PhD
Clin Pharmacol Ther 75: P1-P1; doi:10.1016/j.clpt.2003.11.003
SULT1A1 and UGT1A1 polymorphisms are associated with breast cancer phenotypes in women
E. G. Shatalova MS, T. R. Rebbeck PhD and R. L. Blanchard PhD
Clin Pharmacol Ther 75: P1-P1; doi:10.1016/j.clpt.2003.11.004
ER-alpha and ER-beta genotypes predict tamoxifen effects on serum lipids in breast cancer patients
M. I. Rehman MD, A. Bermes BSc, K. Lee MD, PhD, T. Skaar PhD, M. Arefayene, L. Li PhD, V. Stearns MD, D. A. Flockhart MD, PhD and D. F. Hayes MD
Clin Pharmacol Ther 75: P2-P2; doi:10.1016/j.clpt.2003.11.005
ARG389GLY beta-1 adrenergic receptor polymorphism and left ventricular remodeling changes to beta-blocker therapy
S. G. Terra PharmD, K. K. Hamilton MD, D. F. Pauly MD, PhD, C. R. Lee PharmD, J. Patterson PharmD, K. F. Adams Jr MD, R. S. Schofield MD, J. A. Hill MD, J. M. Aranda MD, H. N. Yarandi PhD and J. A. Johnson PharmD
Clin Pharmacol Ther 75: P2-P2; doi:10.1016/j.clpt.2003.11.006
Lack of development of acute tolerance (AT) to intravenous (IV) ethanol (ETH) in the elderly
P. W. Slattum PharmD, PhD, V. A. Ramchandani PhD and J. Venitz MD, PhD
Clin Pharmacol Ther 75: P2-P2; doi:10.1016/j.clpt.2003.11.007
Comparison of heroin and hydromorphone in opioid users
B. Brands PhD, D. Marsh MD, U. Busto PharmD and A. MacDonald BSc
Clin Pharmacol Ther 75: P3-P3; doi:10.1016/j.clpt.2003.11.008
Probing opioid effects in major depression
U. E. Busto PharmD, L. Tremblay PhD, A. MacDonald BSc, N. Herrmann MD and C. Naranjo MD
Clin Pharmacol Ther 75: P3-P3; doi:10.1016/j.clpt.2003.11.009
An approach to characterize pharmacokinetic-pharmacodynamic bioequivalence of propofol
M. Grossmann MD and U. Ebert IKP GmbH
Clin Pharmacol Ther 75: P3-P3; doi:10.1016/j.clpt.2003.11.010
SCIO-469, a novel P38A MAPK Inhibitor, provides efficacy in acute post-surgical dental pain
S. E. Tong MD, S. E. Daniels DO, T. Montano BSBM, S. Chang PhD and P. Desjardins DMD, PhD
Clin Pharmacol Ther 75: P3-P3; doi:10.1016/j.clpt.2003.11.011
Assessment of visual analog versus categorical scale for measurement of osteoarthritis acute pain
M. Averbuch MD and M. Katzper PhD
Clin Pharmacol Ther 75: P4-P4; doi:10.1016/j.clpt.2003.11.012
Phase Ib clinical trial of aerosolized liposome encapsulated fentanyl (AeroLEF|[trade]|)
O. R. Hung MD, E. M. Sellers MD, H. L. Kaplan PhD and M. K. Romach MD
Clin Pharmacol Ther 75: P4-P4; doi:10.1016/j.clpt.2003.11.013
Effect of a selective COX-2 inhibitor in the development of central sensitization in the oral surgery model
C. C. Picco BA, Y. Lee DDS, MS, B. P. Chuang DMD, S. M. Gordon DDS, MPH, PhD, J. S. Brahim DDS, MS and R. A. Dionne DDS, PhD
Clin Pharmacol Ther 75: P4-P4; doi:10.1016/j.clpt.2003.11.014
The haplotype structure in the gene encoding the delta-opioid receptor in humans
R. K. Krishnaraju PhD, H. S. Kim DDS, PhD, D. A. Goldman MD and R. A. Dionne DDS, PhD
Clin Pharmacol Ther 75: P4-P4; doi:10.1016/j.clpt.2003.11.015
The evaluation of the COX-2 selective inhibition of lumiracoxib, a novel nonsteroidal anti-inflammatory drug
H. Furuie MD, PhD, M. Murakami MD, PhD, K. Matsuguma MD, M. Ishibashi, H. Tsukikawa, M. Kimura PharmD, A. Shishido and S. Irie MD
Clin Pharmacol Ther 75: P5-P5; doi:10.1016/j.clpt.2003.11.016
Population pharmacokinetics (PPK) analysis of A77 1726 (M1) after oral administration of leflunomide (LEF) in pediatric subjects with polyarticular course juvenile rheumatoid arthritis (JRA)
J. Shi MD, S. J. Kovacs PharmD, T. M. Ludden PhD and V. Bhargava PhD
Clin Pharmacol Ther 75: P5-P5; doi:10.1016/j.clpt.2003.11.017
High doses of L-NMMA dilate human hand veins in vivo via EDHF-mediated mechanisms
C. Schindler MD and W. Kirch MD
Clin Pharmacol Ther 75: P5-P5; doi:10.1016/j.clpt.2003.11.018
Changes in serum urea and creatinine during long-term therapy with amiodarone
P. Pollak MD, PhD and F. Alsohaibani MD
Clin Pharmacol Ther 75: P5-P5; doi:10.1016/j.clpt.2003.11.019
Is a different effect on sympathetic nerve activity between nisoldipine and cilnidipine in humans?
T. Shiga MD, M. Wakaumi MD, Y. Yamada MD, N. Matsuda MD, A. Urae MD, M. Hashiguchi PhD, N. Hagiwara MD and H. Kasanuki MD
Clin Pharmacol Ther 75: P6-P6; doi:10.1016/j.clpt.2003.11.020
Autonomic function and QT interval measurements from ambulatory electrocardiography in normal and CAD subjects
T. Callahan PhD, W. Stuppy MD, K. Friday MD, A. Quyyumi MD and H. Gomez MD, PhD
Clin Pharmacol Ther 75: P6-P6; doi:10.1016/j.clpt.2003.11.021
Pharmacokinetic and pharmacodynamic characteristics in healthy volunteers of razaxaban, an orally-active, potent, selective inhibitor of factor XA
A. Swaminathan PhD, C. Frost PharmD, R. Knabb PhD, S. A. Bai PhD, D. Kornhauser MD and R. Mosqueda-Garcia MD, PhD
Clin Pharmacol Ther 75: P6-P6; doi:10.1016/j.clpt.2003.11.022
Assessment of absorption of RHO kinase inhibitor fasudil at different sites of the human gastrointestinal tract
M. Lu PhD, B. Tao MS, M. Pawula PhD, A. Karara PhD, I. Wilding PhD and P. H. Hinderling MD
Clin Pharmacol Ther 75: P6-P6; doi:10.1016/j.clpt.2003.11.023
Effects of P2Y12 inhibition on platelet function in renal transplant patients
J. Graff MD, U. Klinkhardt MD, J. Gossmann MD, O. Wahl and S. Harder MD
Clin Pharmacol Ther 75: P7-P7; doi:10.1016/j.clpt.2003.11.024
Assessing sumatriptan effects on the venous system using a novel approach
K. Burggraaf MD, PhD, K. de Boer, R. Schoemaker PhD and A. Cohen MD, PhD
Clin Pharmacol Ther 75: P7-P7; doi:10.1016/j.clpt.2003.11.025
Experience evaluating QT prolongation data
L. A. Kenna PhD, A. Parekh PhD, V. Jarugula PhD, D. J. Chatterjee PhD, H. Sun PhD, M. J. Kim PharmD, S. Ortiz PhD, J. P. Hunt BS and H. Malinowski PhD
Clin Pharmacol Ther 75: P7-P7; doi:10.1016/j.clpt.2003.11.026
An observation on QT variability in healthy male volunteers
D. G. Wilbraham MBBS, D. Amin MRCGP, M. Angell MRCP and T. Mant FRCP
Clin Pharmacol Ther 75: P8-P8; doi:10.1016/j.clpt.2003.11.028
An evaluation of the FDA draft guidance for estimating the maximum recommended starting dose (MRSD) for first-in-human (FIH) studies
G. Chan PharmD, P. Gray PharmD and P. Glue MD, PhD
Clin Pharmacol Ther 75: P8-P8; doi:10.1016/j.clpt.2003.11.029
A novel method to assess test-quality of phase-3 trials
C. E. Garnett PharmD, J. Nelson MS and C. Peck MD
Clin Pharmacol Ther 75: P8-P8; doi:10.1016/j.clpt.2003.11.030
Survey based FDA experience on submissions with population analysis and/or studies
H. Sun PhD, S. W. Lau PhD, A. Louis PharmD, P. Lee PhD, J. Hunt BS, H. Malinowski PhD and L. Lesko PhD
Clin Pharmacol Ther 75: P8-P8; doi:10.1016/j.clpt.2003.11.031
Assessment of dose response information in drug labeling
D. A. Spyker MD, P. Frohna MD, P. Kuebler PharmD, S. Kelsey MD, A. Joshi PhD, C. Ng PhD, B. Lum PhD, R. Bruno PhD, J. Lu PhD, R. Quesenberry MA, S. Reoriguez BA, D. Giltinan PhD, L. R. Cantilena MD and C. C. Peck MD
Clin Pharmacol Ther 75: P9-P9; doi:10.1016/j.clpt.2003.11.032
Prevalence of the slow metabolizer (SM) phenotype and single dose pharmacokinetics (PK) of desloratadine (DCL) in a population of healthy adults
G. S. Frick, R. A. Blum, S. J. Kovacs, C. Vitow, J. A. Stewart and W. K. Kraft
Clin Pharmacol Ther 75: P9-P9; doi:10.1016/j.clpt.2003.11.033
Pharmacokinetics of a human monoclonal antibody to IL-12 P40 following single intravenous infusion in patients with moderate to severe plaque-type psoriasis
Y. W. Zhu PhD, J. Zhang PhD, C. Pendley PhD, B. Frederick, M. Mascelli PhD, A. B. Gottleib MD, PhD, C. L. Kauffman MD, C. Guzzo MD, H. M. Davis PhD, D. E. Everitt MD and M. A. Graham PhD
Clin Pharmacol Ther 75: P9-P9; doi:10.1016/j.clpt.2003.11.034
Pharmacokinetics of ranitidine and nizatidine in very elderly patients
A. Fujimura MD, M. Sasaki MD and T. Sudoh PhD
Clin Pharmacol Ther 75: P10-P10; doi:10.1016/j.clpt.2003.11.035
Bioequivalence of over-the-counter (OTC) progesterone cream (PC)
A. C. Hermann MD, A. N. Nafziger MD, MHS, J. Victory BSN, RN, M. L. Rocci Jr PhD, R. Kulawy BS and J. S. Bertino Jr PharmD
Clin Pharmacol Ther 75: P10-P10; doi:10.1016/j.clpt.2003.11.036
Differential effects of two types of antidepressants, amitriptyline and fluoxetine, on anorectal motility and visceral perception
E. Bellissant MD, PhD and Laurent Siproudhis MD, PhD
Clin Pharmacol Ther 75: P10-P10; doi:10.1016/j.clpt.2003.11.037
Bile acids stimulate expression of intestinal differentiation markers in gastroesophageal junction (GEJ) adenocarcinoma cells
P. R. Debruyne MD, PhD, S. Schulz PhD and S. A. Waldman MD, PhD, FCP
Clin Pharmacol Ther 75: P10-P10; doi:10.1016/j.clpt.2003.11.038
Nasogastric administration of omepradex for stress ulcer prophylaxis in critically ill patients
L. Arcavi MD and R. Shihmanter MD
Clin Pharmacol Ther 75: P11-P11; doi:10.1016/j.clpt.2003.11.039
Comparison of MK-0767 pharmacokinetics in Japanese and non-Japanese subjects
H. Zhu PhD, X. Chen PhD, R. K. Rippley PhD, E. M. Migoya PharmD, C. Toriumi PhD, K. Hamada BSc and J. A. Wagner MD, PhD
Clin Pharmacol Ther 75: P11-P11; doi:10.1016/j.clpt.2003.11.040
An experimental therapeutic approach to genetically-based obesity
J. Licinio, S. Caglayan, M. Ozata, B. Yildiz, P. de Miranda, F. O'Kirwan, S. Bhasinm, R. M. Krauss, J. Veldhuis, A. Wagner, A. dePaoli and M. Wong
Clin Pharmacol Ther 75: P11-P11; doi:10.1016/j.clpt.2003.11.041
Effect of omeprazole on brain-gut peptides concentrations in human plasma
S. Inoue, F. Katagiri, Y. Sato, H. Itoh and M. Takeyama PhD
Clin Pharmacol Ther 75: P11-P11; doi:10.1016/j.clpt.2003.11.042
The bradykinin antagonist icatibant increases electrolyte and water excretion after sodium challenge in patients with liver cirrhosis
S. Russmann MD, L. Decosterd PhD, T. Buclin MD, T. Schwaar RN, S. Baumann PhD, F. Brunner-Ferber MD, B. Rosenkranz, J. Knolle and J. Reichen MD
Clin Pharmacol Ther 75: P12-P12; doi:10.1016/j.clpt.2003.11.043
Effect of SRD5A2 genotype on pharmacodynamics of 5-alpha-reductase inhibitor analyzed by PK-PD modeling
J. Chung MD, J. Cho PhD, H. Lim MD, D. Oh OMD, S. Yi MS, I. Jang MD, PhD and S. Shin MD, PhD
Clin Pharmacol Ther 75: P12-P12; doi:10.1016/j.clpt.2003.11.044
Towards a mechanistic disease progression model for type 2 diabetes mellitus
W. de Winter PhD, J. DeJongh PhD, D. Eckland PhD and M. Danhof PhD PharmD
Clin Pharmacol Ther 75: P12-P12; doi:10.1016/j.clpt.2003.11.045
The effects of losartan and losartan/hydrochlorothiazide fixed combination on zinc and magnesium metabolism in patients with hypertension
V. Dishy MD, M. Koren-Michowitz MD, R. Zaidenstein MD, S. Berman MS, O. Yona BSc and A. Golik MD
Clin Pharmacol Ther 75: P12-P12; doi:10.1016/j.clpt.2003.11.046
Nitric oxide bioavailability is also regulated by the CGMP pathway in L-NAME hypertensive cardiomyopathy of rats
S. Ferreira-Melo PharmD, J. C. Yugar-Toledo MD, W. A. Souza PharmD, A. J. Thomaz, K. G. Franchini MD, PhD, O. R. Coelho MD, PhD, I. de Lucca MD, PhD and H. Moreno MD, PhD
Clin Pharmacol Ther 75: P13-P13; doi:10.1016/j.clpt.2003.11.047
Beta-2 adrenergic receptor polymorphisms and blood pressure responses to salt
G. G. Sofowora MD, V. Dishy MD, M. Muszkat MD, H. Xie MD PhD, H. C. Prasad MD PhD, A. J. Wood MD and C. M. Stein MD
Clin Pharmacol Ther 75: P13-P13; doi:10.1016/j.clpt.2003.11.048
Effect of alpha-2C adrenergic receptor (ADRA2C) 322-325 deletion polymorphism on blood pressure response to dietary sodium in African-Americans (AA)
M. Muszkat MD, G. Sofowora MD, V. Dishy MD, H. Xie MD, PhD, P. A. Harris PhD, A. J. Wood MD and C. Stein MD
Clin Pharmacol Ther 75: P13-P13; doi:10.1016/j.clpt.2003.11.049
Association of CYP3A5|[ast]|3, |[ast]|6, and |[ast]|7 polymorphisms with hypertension
T. Y. Langaee PhD, R. C. Givens BS, A. Sloan MS, P. B. Watkins MD and J. A. Johnson PharmD
Clin Pharmacol Ther 75: P13-P13; doi:10.1016/j.clpt.2003.11.050
An osmotic bioequivalent nifedipine tablet
E. C. Feleder MD, PhD, M. Befumo BCh, M. A. Ricci Pharm, M. A. Coppari BCh and J. Faour PhD
Clin Pharmacol Ther 75: P14-P14; doi:10.1016/j.clpt.2003.11.051
Palatability of antiretroviral drugs in children with HIV: A 16-year retrospective study in a large urban centre
D. Lin, M. J. Rieder MD, PhD and S. M. King
Clin Pharmacol Ther 75: P14-P14; doi:10.1016/j.clpt.2003.11.052
Comparison of imipenem/cilastatin (I/C) and meropenem (M) attainment of pharmacodynamic (PD) target goals at various dosage regimens using a short (30-min) infusion time
L. S. Lee PharmD, L. S. Lee PharmD and J. S. Bertino Jr. PharmD
Clin Pharmacol Ther 75: P14-P14; doi:10.1016/j.clpt.2003.11.053
Use of a prolonged infusion time (3-hr) in attaining pharmacodynamic (PD) target goals of imipenem-cilastatin (I/C) AND meropenem (M) at various dosing regimens
L. S. Lee PharmD and J. S. Bertino Jr PharmD
Clin Pharmacol Ther 75: P15-P15; doi:10.1016/j.clpt.2003.11.054
Effect of semen sampling frequency on concentrations of zidovudine and male genital tract glandular markers, fructose, PSA, and sperm count
T. T. Ndovi MD, J. I. Lee BsC, F. Hamzeh MD, PhD and C. W. Hendrix MD
Clin Pharmacol Ther 75: P15-P15; doi:10.1016/j.clpt.2003.11.055
Evaluation of intracellular ascorbate deficiency and the cytotoxicity of sulfamethoxazole nitroso in healthy and HIV-infected subjects
L. A. Trepanier DVM, PhD, M. V. Guzinski, J. E. Maki, A. R. Yoder, S. Bajad PhD, J. L. Bellehumeur RN, M. D. Beckwith RN and F. M. Graziano MD, PhD
Clin Pharmacol Ther 75: P15-P15; doi:10.1016/j.clpt.2003.11.056
Population pharmacokinetic model for nelfinavir and its active metabolite hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1
E. Jacqz-Aigrain, S. Payen, A. Faye, A. Compagnucci, C. Giaquinto and F. Bressolle
Clin Pharmacol Ther 75: P15-P15; doi:10.1016/j.clpt.2003.11.057
Risk of undertreatment with the standard abacavir 300 mg dose
V. Jullien PharmD, S. Urien D, PhD, J. Dimet PharmD, E. Rey PharmD, N. Dupin MD, D. Salmon MD, PhD, G. Pons MD, PhD and J. Treluyer MD, PhD
Clin Pharmacol Ther 75: P16-P16; doi:10.1016/j.clpt.2003.11.058
Effect of beta-1 adrenergic receptor polymorphisms on the tolerability of metoprolol CR/XL in heart failure
S. G. Terra PharmD, D. F. Pauly MD, PhD, C. R. Lee PharmD, J. Patterson PharmD, K. F. Adams Jr MD, R. S. Schofield MD, K. K. Hamilton MD, J. A. Hill MD, J. M. Aranda MD and J. A. Johnson PharmD
Clin Pharmacol Ther 75: P16-P16; doi:10.1016/j.clpt.2003.11.059
Pharmacogenetics of CYP2C8 and haplotypic associations in three distinct Asian populations
C. Kibat B.Sc, Q. Zhou PhD, H. Li PhD and B. Chowbay PhD
Clin Pharmacol Ther 75: P16-P16; doi:10.1016/j.clpt.2003.11.060
Functional characterization of MDR3 promoter mutations detected in intrahepatic cholestasis of pregnancy
C. Pauli-Magnus MD, T. Lang PhD, D. Jung PhD, G. A. Kullak-Ublick MD and P. J. Meier MD
Clin Pharmacol Ther 75: P16-P16; doi:10.1016/j.clpt.2003.11.061
The influences of human MDR1 gene polymorphisms on pharmacokinetics of tacrolimus in renal transplant recipients
S. Uchida PhD, N. Takai, H. Hashimoto PhD, H. Furuse MD, S. Kageyama MD, PhD, T. Ushiyama MD, PhD, K. Suzuki MD, PhD, S. Ozono MD, PhD, H. Yamada MD, PhD, H. Watanabe MD, PhD and K. Ohashi MD, PhD
Clin Pharmacol Ther 75: P17-P17; doi:10.1016/j.clpt.2003.11.062
Transcriptional regulation of CYP3A7 by P53
N. Matsumoto MD, PhD, T. Kumai PhD, Y. Takeba PhD, M. Watanabe PhD, K. Kamio MD, R. Taniguchi MD, Y. Koitabashi MD and S. Kobayashi MD, PhD
Clin Pharmacol Ther 75: P17-P17; doi:10.1016/j.clpt.2003.11.063
Molt-4 rho(0) cells up regulate stress-induced survival genes in an attempt to overcome the potentially lethal consequence of mitochondrial DNA depletion
A. J. Olszanski MD, M. L. LaCroix-Fralish, R. Armand, R. P. Perez, MD and L. D. Lewis MD
Clin Pharmacol Ther 75: P17-P17; doi:10.1016/j.clpt.2003.11.064
Association of C3435T and G2677T/A polymorphisms of multidrug resistance (MDR1) gene with colorectal cancer risk
E. Gaikovitch MD, P. Mrozikievicz MD, F. Wagner PD and I. Roots MD
Clin Pharmacol Ther 75: P17-P17; doi:10.1016/j.clpt.2003.11.065
Interaction of cladribine and fludarabine with genetic variants in the concentrative nucleoside transporter, CNT3
I. Badagnani PharmD and K. M. Giacomini PhD
Clin Pharmacol Ther 75: P18-P18; doi:10.1016/j.clpt.2003.11.066
The effect of CYP2D6 genotype on the pharmacokinetics of lovastatin in Chinese subjects
O. Q. Yin PhD, Q. Chang PhD, B. Tomlinson MD and M. S. Chow Pharm D
Clin Pharmacol Ther 75: P18-P18; doi:10.1016/j.clpt.2003.11.067
The effect of polymorphism on serotonin and histamine reseptor in antipsychotic action of olanzapine
T. Amamoto MD, S. Nakaya, T. Kumai PhD, Y. Morokawa MD, PhD, K. Gen MD, PhD, H. Suzuki MD, PhD, T. Akimoto MD, A. Aoba MD, PhD and S. Kobayashi MD, PhD
Clin Pharmacol Ther 75: P18-P18; doi:10.1016/j.clpt.2003.11.068
Inter- and intraindividual variability of urinary dextromethorphan/dextrorphan (DM/DX) ratios in CYP2D6 extensive metabolizers (EMS) with one or two active alleles
J. D. Ma PharmD, J. S. Bertino Jr PharmD, A. Gaedigk PhD, MS, A. D. Kashuba PharmD, D. S. Streetman PharmD and A. N. Nafziger MD, MHS
Clin Pharmacol Ther 75: P18-P18; doi:10.1016/j.clpt.2003.11.069
Metoprolol pharmacokinetics and pharmacodynamics in carriers of CYP2D6 genotypes predicting ultra-rapid metabolism
J. Kirchheiner MD, C. Meisel MD, C. Heesch MS, S. Bauer, PhD, T. Keulen MS, H. Henckel MS, I. Roots MD and J. Brockm|[ouml]|ller MD
Clin Pharmacol Ther 75: P19-P19; doi:10.1016/j.clpt.2003.11.070
Enantio-preferential effects of the CYP2D6 genotype on bioavailability and systemic clearance of the tricyclic antidepressant trimipramine
J. Kirchheiner MD, I. Meineke PhD, J. Brockm|[ouml]|ller MD and I. Roots MD
Clin Pharmacol Ther 75: P19-P19; doi:10.1016/j.clpt.2003.11.071
Thiopurine S-methyltransferase (TPMT) pharmacogenetics: variant allele functional genomics
O. E. Salavaggione MD, M. Wiepert and R. M. Weinshilboum MD
Clin Pharmacol Ther 75: P19-P19; doi:10.1016/j.clpt.2003.11.072
Pharmacological characterization of 4-hydroxy-n-desmethyl-tamoxifen (ENDOXIFEN) AND 4-hydroxy-tamoxifen (4OHTAM)
Y. Lim MD, PhD, T. C. Skaar PhD, R. V. Weatherman PhD, Z. Desta PhD, A. Bermes BSc, D. A. Flockhart MD, PhD and M. D. Johnson PhD
Clin Pharmacol Ther 75: P19-P19; doi:10.1016/j.clpt.2003.11.073
Evaluation of safety, tolerability, and pharmacokinetic characteristics of B-domain deleted recombinant FVIII in hemophilia a patients
J. Kim MD, J. Chung MD, H. Lim MD, D. Oh OMD, J. Cho PhD, H. Chung, S. Yi MS, I. Jang MD, PhD and S. Shin MD, PhD
Clin Pharmacol Ther 75: P20-P20; doi:10.1016/j.clpt.2003.11.074
Pharmacogenetics of CYP3A5 and effects of corticosteroids in children treated for acute lymphoblastic leukemia
C. Dupont, Y. Medard, H. Cave, E. Vilmer and E. Jacqz-Aigrain
Clin Pharmacol Ther 75: P20-P20; doi:10.1016/j.clpt.2003.11.075
CYP2C9 genotyping and phenotyping in Brazilians: effects on the pharmacokinetics of the NSAID tenoxicam
G. Suarez-Kurtz MD, DoctMed, J. A. Perini PharmD and R. Vianna-Jorge Pharm D, PhD,
Clin Pharmacol Ther 75: P20-P20; doi:10.1016/j.clpt.2003.11.076
Binding of [123I]beta-CIT to brain serotonin and dopamine transporters (SERT & DAT) after multiple dose administration of sertraline
M. A. Gibbs PhD, J. F. Rogers PharmD, G. J. Marek MD, PhD, T. R. Stiger PhD, K. L. Marek MD and J. P. Seibyl MD
Clin Pharmacol Ther 75: P20-P20; doi:10.1016/j.clpt.2003.11.077
The effect of omeprazole on the bioavailability of sodium oxybate
L. A. Borgen PhD, D. Morrison DO and A. Lai PhD
Clin Pharmacol Ther 75: P21-P21; doi:10.1016/j.clpt.2003.11.078
Differential effects of methadone dose/contingency management combinations on abstinence from heroin and cocaine
K. L. Preston PhD, J. Schmittner MD, J. R. Schroeder PhD, S. J. Boyd MD, E. T. Moolchan MD and D. H. Epstein PhD
Clin Pharmacol Ther 75: P21-P21; doi:10.1016/j.clpt.2003.11.079
Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ascending single doses of SRA-333 in healthy subjects
A. A. Patat MD, V. Parks BSc, S. Raje PhD, A. Plotka PhD and D. Chassard MD
Clin Pharmacol Ther 75: P21-P21; doi:10.1016/j.clpt.2003.11.080
Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ascending multiple doses of SRA-333 in healthy subjects
A. A. Patat MD, V. Parks BSc, S. Raje PhD, A. Plotka PhD and D. Chassard MD
Clin Pharmacol Ther 75: P21-P21; doi:10.1016/j.clpt.2003.11.081
Pharmacokinetics and tolerability of the combination of lamotrigine (LTG) and oxcarbazepine (OXC) in healthy volunteers
J. G. Theis MD, J. Sidhu PhD, S. Job MSc, J. E. Palmer PhD, J. M. Ratcliffe and J. A. Ascher MD
Clin Pharmacol Ther 75: P22-P22; doi:10.1016/j.clpt.2003.11.082
Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts
K. Fattinger MD, F. Girardin MD, K. M. Rentsch PhD, M. A. Schwab MD, M. Maggiorini MD, C. Pauli-Magnus MD, G. A. Kullak-Ublick MD and P. J. Meier MD
Clin Pharmacol Ther 75: P22-P22; doi:10.1016/j.clpt.2003.11.083
Study of the absorption, metabolism, and excretion of (14C)-ramelteon (TAK-375)
S. Stevenson PhD, K. Cornelissen PhD, E. Clarke and M. Hibberd
Clin Pharmacol Ther 75: P22-P22; doi:10.1016/j.clpt.2003.11.084
Study to investigate the absolute bioavailability of a single oral dose of ramelteon (TAK-375) in healthy male subjects
S. Stevenson PhD, S. Bryson PhD, D. Amakye MBChB, DCH, MFPM and M. Hibberd
Clin Pharmacol Ther 75: P22-P22; doi:10.1016/j.clpt.2003.11.085
Treating chronic pediatric conditions: pirenzepine ophthalmic gel (PIR) for the slowing of progression of pediatric myopia as a model pediatric development program
G. D. Novack PhD, R. S. Crockett PhD, P. Lopez and M. Edmondson
Clin Pharmacol Ther 75: P23-P23; doi:10.1016/j.clpt.2003.11.086
Dose-response relationship of increasing doses of dextromethorphan given to children with cough
I. M. Paul MD, MSc, K. E. Yoder, S. A. Sturgis RN, CRNP, M. S. Baker MD, M. L. Shaffer PhD and C. M. Berlin Jr MD
Clin Pharmacol Ther 75: P23-P23; doi:10.1016/j.clpt.2003.11.087
The transfer of glyburide into breast milk
D. S. Feig, J. M. Kraemer, D. N. Moskovitz, D. Donat and G. Koren
Clin Pharmacol Ther 75: P24-P24; doi:10.1016/j.clpt.2003.11.089
The pediatric module at the coordination center for clinical trials heidelberg-an approach to improve quality and conduct of clinical drug trials in children
U. Ebert MD, R. Feneberg MD, B. Toenshoff MD and M. Seibert-Grafe MD
Clin Pharmacol Ther 75: P24-P24; doi:10.1016/j.clpt.2003.11.090
Steady state pharmacokinetic study of FLAGYL|[reg]| ER in pregnant patients during the second to third trimester of pregnancy
C. Stika MD, W. Andrews MD, M. Frederiksen MD, B. Mercer MD, B. Sibai MD and E. Antal PhD
Clin Pharmacol Ther 75: P24-P24; doi:10.1016/j.clpt.2003.11.091
Ontogeny of renal P-glycoprotein expression in mice: implications for pediatric dosing
N. Pinto, N. Halachmi PhD, C. Woodland PhD and G. Koren MD
Clin Pharmacol Ther 75: P25-P25; doi:10.1016/j.clpt.2003.11.092
Pregvit: an alternate prenatal supplement for women with nausea and vomiting in pregnancy
E. Ahn, B. Kapur, A. Einarson and G. Koren
Clin Pharmacol Ther 75: P25-P25; doi:10.1016/j.clpt.2003.11.093
Fluvoxamine (LUVOX|[trade]|) use in pregnancy
A. Sivojelezova BSc
Clin Pharmacol Ther 75: P25-P25; doi:10.1016/j.clpt.2003.11.094
The use of fatty acid ethyl esters in neonatal hair to identify infants affected by prenatal alcohol exposure: a baseline study
D. L. Caprara BSc, J. Klein MSc and G. Koren MD
Clin Pharmacol Ther 75: P25-P25; doi:10.1016/j.clpt.2003.11.095
Increased reactive oxygen stress in cells of patients with drug hypersensitivity
M. J. Rieder MD, PhD, V. Cukernik, G. Oakes and J. Bend PhD
Clin Pharmacol Ther 75: P26-P26; doi:10.1016/j.clpt.2003.11.096
Time-dependent toxicity of sulfonamide reactive metabolites in cells of patients with sulfonamide hypersensitivity
V. Cukernik and M. J. Rieder MD, PhD
Clin Pharmacol Ther 75: P26-P26; doi:10.1016/j.clpt.2003.11.097
Triangular test (TT), a sequential approach for comparative trials in children
G. Pons MD, PhD, J. Hulot MD, J. Treluyer MD, PhD, C. Chiron MD, PhD, S. Tonnelier PharmD and P. Lechat MD, PhD
Clin Pharmacol Ther 75: P26-P26; doi:10.1016/j.clpt.2003.11.098
Pharmacokinetics (PK) and pharmacodynamics (PD) of enfuvirtide in hiv-1 infected adolescents over 24 weeks of treatment
X. Zhang PhD, A. Dorr PhD, Z. Siddique MPharm, A. Bertasso MS, L. Rowell MS and S. Kolis MS
Clin Pharmacol Ther 75: P26-P26; doi:10.1016/j.clpt.2003.11.099
Over-the-counter vitamin K1-Containing multivitamin supplements disrupt oral anticoagulation in susceptible patients-a prospective trial
D. Kurnik MD, H. Rabinovitz BSc, R. Loebstein MD, N. Austerweil BSc, S. Almog PhD and H. Halkin MD
Clin Pharmacol Ther 75: P27-P27; doi:10.1016/j.clpt.2003.11.100
A double blind comparison of the opiate antagonist, naltrexone and promethazine in the prophylaxis or palliation of chloroquine induced pruritus in malaria fever
A. Ajayi MD, PhD and B. A. Kolawole MD
Clin Pharmacol Ther 75: P27-P27; doi:10.1016/j.clpt.2003.11.101
Are brand-name and generic warfarin interchangeable?
J. A. Pereira MSc, A. M. Holbrook MD, L. Dolovich PharmD, J. D. Douketis MD, M. A. Crowther MD, S. M. Bates MD, J. R. Ginsberg MD, C. Goldsmith PhD and L. Thabane PhD
Clin Pharmacol Ther 75: P27-P27; doi:10.1016/j.clpt.2003.11.103
Natural health product use in Canada: patterns of use and the risk of interactions with pharmaceuticals
S. R. Singh and M. Levine MD
Clin Pharmacol Ther 75: P28-P28; doi:10.1016/j.clpt.2003.11.104
Geographic variation in indicators of opiate abuse and treatment availability in California
J. E. Mendelson MD and N. Lodhia BA
Clin Pharmacol Ther 75: P28-P28; doi:10.1016/j.clpt.2003.11.105
Effect of fluvastatin on CYP2C9 activity using warfarin as a probe
M. Kim PharmD, A. N. Nafziger MD, MHS, J. Kirchheiner MD, S. Bauer PhD, A. Gaedigk PhD and J. S. Bertino Jr. PharmD, F.D.A.
Clin Pharmacol Ther 75: P28-P28; doi:10.1016/j.clpt.2003.11.106
Dose-dependent pharmacokinetics (PK) of short IV infusions of selodenoson (DTI-0009), a novel adenosine (A1-) receptor agonist, in healthy subjects
J. Venitz MD, PhD, A. Y. Men MD, R. W. Townsend RN, PhD and M. Dessimoz BS
Clin Pharmacol Ther 75: P28-P28; doi:10.1016/j.clpt.2003.11.107
Decreased bioavailability of rifampicin and other anti-tb drugs in patients with advanced HIV disease
P. Gurumurthy PhD, DSc, FABMS, G. Ramachandran PhD, A. Hemanthkumar PhD, S. Rajasekaran MD, DTCD, C. Padmapriyadarsini MBBS, MS, S. Swaminathan MD, S. Bhagavathy MSc, MPhil, P. Venkatesan PhD MPS PGCDM D, L. Sekar MSc, A. Mahilmaran MBBS, N. Ravichandran MBBS and P. Paramesh MD
Clin Pharmacol Ther 75: P29-P29; doi:10.1016/j.clpt.2003.11.108
Effect of multiple doses of fenofibrate on the pharmacokinetics of pravastatin
L. E. Gustavson PhD, S. M. Schweitzer, S. Koehne-Voss, R. Achari PhD, T. Chira, H. Esslinger MD and H. D. Yannicelli MD
Clin Pharmacol Ther 75: P29-P29; doi:10.1016/j.clpt.2003.11.109
Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam
A. Fujimura MD, K. Sugimoto MD, N. Araki PharmD, M. Ohmori MD, Y. Cui PhD, S. Tsuruoka MD and A. Kawaguchi PharmD
Clin Pharmacol Ther 75: P29-P29; doi:10.1016/j.clpt.2003.11.110
Population pharmacokinetics analysis of patients receiving enoxaparin by continuous intravenous infusion
Y. Feng, R. R. Bies PhD, PharmD, M. B. Bobek PharmD and S. L. Kane PharmD
Clin Pharmacol Ther 75: P30-P30; doi:10.1016/j.clpt.2003.11.112
Accurate vs. approximate likelihood methods in population analysis of sparse data sets
R. H. Leary PhD, R. Jelliffe MD, A. Schumitzky PhD and R. E. Port MD
Clin Pharmacol Ther 75: P30-P30; doi:10.1016/j.clpt.2003.11.113
Evaluate human PK prediction of compound LY based on allometric scaling with three species
S. Mu PhD, S. Anderson PhD and S. Mahadevan PhD
Clin Pharmacol Ther 75: P30-P30; doi:10.1016/j.clpt.2003.11.114
Plasma and cerebrospinal fluid (CSF) pharmacokinetics of CP-457,920, a selective alpha 5 GABA-A receptor inverse agonist in young, healthy volunteers
M. Bednar MD, PhD, C. Chieffo VMD, PhD, T. Morse, M. Duplin RN, BSN and M. A. Gibbs PhD
Clin Pharmacol Ther 75: P30-P30; doi:10.1016/j.clpt.2003.11.115
Population pharmacokinetics (POPPK) of valproic acid (VPA) following rapid infusion in epilepsy patients
S. Dutta PhD and J. C. Cloyd PharmD
Clin Pharmacol Ther 75: P31-P31; doi:10.1016/j.clpt.2003.11.116
Oral clotrimazole (CLZ) decreases presystemic metabolism of cytochrome P450 (CYP) 3A4 substrates
S. S. Shord PharmD, L. Chan PharmD, J. R. Camp BSc, E. Vasquez PharmD, C. Baum MD and R. E. Molokie MD
Clin Pharmacol Ther 75: P31-P31; doi:10.1016/j.clpt.2003.11.117
Celecoxib pharmacokinetics in pediatric cancer patients|[ndash]|The effects of food and pharmacogenetics
D. C. Stempak MSc, B. L. Bukaveckas PhD, M. W. Linder PhD, G. Koren MD and S. Baruchel MD
Clin Pharmacol Ther 75: P31-P31; doi:10.1016/j.clpt.2003.11.118
Clinical pharmacology of tezosentan, a dual endothelin receptor antagonist, in patients with liver cirrhosis
J. Dingemanse PhD, PharmD, A. Halabi MD, P. Hoever MSc, H. Chadha-Boreham PhD and P. L. van Giersbergen PhD
Clin Pharmacol Ther 75: P31-P31; doi:10.1016/j.clpt.2003.11.119
The safety, tolerability and pharmacodynamic responses of interferon BETA-1A (Rebif|[reg]|) versus interferon BETA-1B (Betaseron|[reg]|) in healthy male volunteers
S. Gariepy MSc, J. Marier PhD, D. Potvin MSc, M. Di Marco PhD, W. Byrnes and A. Abdul-Ahad PhD
Clin Pharmacol Ther 75: P32-P32; doi:10.1016/j.clpt.2003.11.120
Nelfinavir (NFV) population pharmacokinetics (PK) in long-term suppressors compared with the pk of the new 625 mg formulation in healthy volunteers
E. Capparelli PharmD, F. D. Goebel MD, I. Williams MD, M. Opravil MD, M. Nelson MD, E. Daniels MD, E. Pun PhD and P. Hsyu PhD
Clin Pharmacol Ther 75: P32-P32; doi:10.1016/j.clpt.2003.11.121
Nonlinear mixed effects model analysis of the pharmacokinetics of metoprolol in middle-aged and elderly Japanese patients
M. Taguchi MS, T. Nozawa MD, PhD, K. Mizumaki MD, PhD, H. Inoue MD, PhD, K. Tahara BS, C. Takesono BS and Y. Hashimoto PhD
Clin Pharmacol Ther 75: P32-P32; doi:10.1016/j.clpt.2003.11.122
Pharmacokinetics of single and multiple escalating doses of dapoxetine in healthy volunteers
M. Dresser PhD, K. Lindert MD, D. Lin MS, S. Gidwani MS, S. K. Gupta PhD and N. B. Modi PhD
Clin Pharmacol Ther 75: P32-P32; doi:10.1016/j.clpt.2003.11.123
The contraceptive vaginal ring, nuvaring, shows no interaction with broad spectrum oral antibiotics
P. Dogterom PhD, M. van den Heuvel MSc and T. Thomsen MD
Clin Pharmacol Ther 75: P33-P33; doi:10.1016/j.clpt.2003.11.124
An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers
P. Mathew, T. Cuddy MS, W. G. Tracewell PhD and D. Salazar PhD
Clin Pharmacol Ther 75: P33-P33; doi:10.1016/j.clpt.2003.11.125
Pharmacokinetic (PK) interaction study of sirolimus (SRL) and cyclosporine (CSA)
A. Patat MD, J. J. Zimmerman PhD, V. Parks BSc and J. Richards MD
Clin Pharmacol Ther 75: P33-P33; doi:10.1016/j.clpt.2003.11.126
Effect of rofecoxib, etoricoxib, celecoxib, and naproxen on urinary excretion of prostanoids in elderly volunteers
J. I. Schwartz PharmD, MPH, K. Vandormael MS, C. Thach PhD, K. C. Lasseter MD, G. B. Holmes PharmD, J. L. Miller BS, D. Hreniuk BS, D. Hilliard BS, K. M. Snyder MS, B. J. Gertz MD, PhD and K. M. Gottesdiener MD
Clin Pharmacol Ther 75: P34-P34; doi:10.1016/j.clpt.2003.11.127
Initial antipyrine disposition in man is altered by propranolol
M. J. Avram PhD, T. K. Henthorn MD, C. U. Niemann MD, C. A. Shanks MD and T. C. Krejcie MD
Clin Pharmacol Ther 75: P34-P34; doi:10.1016/j.clpt.2003.11.128
Effect of rifampin on the pharmacokinetics of rosiglitazone in korean healthy subjects
J. Park MD, K. Kim PhD, W. Jung MD, PhD, S. Kim and J. Shin MD, PhD
Clin Pharmacol Ther 75: P34-P34; doi:10.1016/j.clpt.2003.11.129
Pharmacokinetics (PK) of intraveneous scopolamine (SCP) plus physostigmine (PHY) in healthy elderly male and female volunteers
A. Men MD, PhD cand. and J. Venitz MD, PhD
Clin Pharmacol Ther 75: P34-P34; doi:10.1016/j.clpt.2003.11.130
Renal function and albumin concentration are determinants of mycophenolic acid pharmacokinetics
R. M. van Hest PharmD, T. van Gelder MD, PhD, A. G. Vulto PharmD, PhD and R. A. Mathot PharmD, PhD
Clin Pharmacol Ther 75: P35-P35; doi:10.1016/j.clpt.2003.11.131
Assessment of biliary excretion in humans using a novel oroenteric tube
B. M. Johnson PhD, G. Ghibellini MS, W. D. Heizer MD and K. L. Brouwer PharmD, PhD
Clin Pharmacol Ther 75: P35-P35; doi:10.1016/j.clpt.2003.11.132
Absence of circadian variation in the pharmacokinetics (PK) of lopinavir/ritonavir (LPV/R) in a once-daily (QD) dosing regimen in HIV-1-infected subjects
R. van Heeswijk PharmD, PhD,, M. Bourbeau BSc, I. Seguin RN, D. Cote RN, P. Giguere BPharm, G. Garber MD and B. Cameron MD
Clin Pharmacol Ther 75: P35-P35; doi:10.1016/j.clpt.2003.11.133
ASsessment of botanical supplementation on human cytochrome P450 phenotype: citrus aurantium, echinacea, milk thistle, saw palmetto.
B. J. Gurley PhD, S. F. Gardner PharmD, M. A. Hubbard MS, K. Williams PhD, B. Gentry MD, J. Carrier PhD, D. Edwards PhD and I. Khan PhD, UAMS
Clin Pharmacol Ther 75: P35-P35; doi:10.1016/j.clpt.2003.11.134
Oral contraceptives induce CYP2A6 activity and accelerate nicotine metabolism
N. L. Benowitz MD, G. L. Swan PhD, C. N. Lessov PhD and P. Jacob III PhD
Clin Pharmacol Ther 75: P36-P36; doi:10.1016/j.clpt.2003.11.135
Green tea and irinotecan metabolism
S. Mirkov MS, B. J. Komoroski PharmD, J. Ramirez MS, J. Chandler BS, A. Yoder Graber BS, M. J. Ratain MD, S. C. Strom PhD and F. Innocenti MD
Clin Pharmacol Ther 75: P36-P36; doi:10.1016/j.clpt.2003.11.136
Lack of correlation between lymphocytic mrna expression and activity of CYP3A4 and CYP2E1 In-vivo in alcoholics and non-alcoholics
D. Kolwankar PhD, J. Gorski PhD, S. Liangpunsakul MD, N. Chalasani MD, D. W. Crabb MD and S. D. Hall PhD
Clin Pharmacol Ther 75: P36-P36; doi:10.1016/j.clpt.2003.11.137
Pharmacokinetics and safety of mirtazapine in caucasian and japanese young healthy male volunteers
P. Peeters PhD, M. Brett MA, M. v. Heuvel MSc and A. Sitsen MD
Clin Pharmacol Ther 75: P36-P36; doi:10.1016/j.clpt.2003.11.138
Lack of clinically significant interaction between steady state tolvaptan and digoxin in healthy volunteers
S. E. Shoaf PhD, Z. Wang MD, S. Mallikaarjun PhD, P. Bricmont PhD and S. L. Bramer PhD
Clin Pharmacol Ther 75: P37-P37; doi:10.1016/j.clpt.2003.11.139
Clobazam metabolism by c DNA-expressed human CYP
G. Pons MD, PhD, C. Giraud, A. Tran PharmD, PhD, E. Rey PharmD and J. Treluyer MD, PhD
Clin Pharmacol Ther 75: P37-P37; doi:10.1016/j.clpt.2003.11.140
Effect of chronic heart failure on the pharmacokinetics of eplerenone following single and multiple dosing
W. R. Ravis PhD, S. Reid MEd, P. J. Van Ess PhD, J. Ferry PhD and D. Tolbert PhD
Clin Pharmacol Ther 75: P37-P37; doi:10.1016/j.clpt.2003.11.141
Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment
W. R. Ravis PhD, T. J. Stokes MD, S. Reid MEd, P. J. Van Ess PhD, B. Roniker MD, D. Sica MD and D. Tolbert PhD
Clin Pharmacol Ther 75: P37-P37; doi:10.1016/j.clpt.2003.11.142
Effect of CYP3A-inhibitor and -inducer on the pharmacokinetics of intravenous midazolam in CYP3A5|[ast]|3 allele carriers
J. Cho PhD, K. Hong MD, J. Chung MD, D. Oh OMD, J. Kim MD, H. Lim MD, S. Yi, H. Chung, K. Liu PhD, J. Shin MD, PhD, K. Yu MD, PhD, S. Shin MD, PhD and I. Jang MD, PhD
Clin Pharmacol Ther 75: P38-P38; doi:10.1016/j.clpt.2003.11.143
In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude
K. Venkatakrishnan PhD, R. Obach PhD, K. Bertelsen BS, L. L. von Moltke MD and D. J. Greenblatt MD
Clin Pharmacol Ther 75: P38-P38; doi:10.1016/j.clpt.2003.11.144
Nicotine metabolism in pregnant smokers measured by segmental hair analysis
P. Blanchette BSc, J. Klein MSc, J. Christodouleas, M. Kramer MD and G. Koren MD
Clin Pharmacol Ther 75: P38-P38; doi:10.1016/j.clpt.2003.11.145
Pharmacokinetics and tissue distribution of a new mesalamine rectal gel in ulcerative colitis patients
G. Aumais MD, M. Lefebvre PhD, J. Massicotte BSc, C. Tremblay BSc, J. Kasbo MSc, J. Brunet MSc, C. Cardinal MSc and J. Sp|[eacute]|nard PhD
Clin Pharmacol Ther 75: P38-P38; doi:10.1016/j.clpt.2003.11.146
Population pharmacokinetic modeling of ephedrine, norephedrine and caffeine in healthy subjects
C. Csajka PhD, C. A. Haller MD, N. L. Benowitz MD and D. Verotta PhD
Clin Pharmacol Ther 75: P39-P39; doi:10.1016/j.clpt.2003.11.147
Pharmacokinetics and immunogenicity profiles for fully human monoclonal antibodies against soluble and membrane bound antigens in patients with psoriasis and melanoma
M. Tabrizi PhD, L. Roskos PhD, H. Lu MS, N. Raie MS, C. Funelas BS, S. Holtzclaw BS, R. Pasumarthi MS, Z. To BS, M. Wyres MS, G. Bell MD and G. Schwab MD
Clin Pharmacol Ther 75: P39-P39; doi:10.1016/j.clpt.2003.11.148
Cytochrome P-450 3A4, 3A5, and MDR-1 as pharmacogenomic predictors of tacrolimus pharmacokinetics and clinical outcomes in liver transplant recipients
C. Formea PharmD, T. Luu BS, A. Albekairy PharmD, H. Yarandi PhD, T. Langee PhD, V. Greene PA, S. Fuijita MD, W. van der Werf MD, A. Hemming MD, R. Howard MD, PhD, A. Reed MD and J. Karlix PharmD
Clin Pharmacol Ther 75: P39-P39; doi:10.1016/j.clpt.2003.11.149
Use of statistical simulation and design optimization to plan a successful repeat bioequivalence study
V. Sethuraman MS, M. Hossain PhD, S. Guerrera PhD, S. Dunbar PhD, A. Graham MSPH, R. Pypstra MD, R. Causon PhD and J. Aluri MS
Clin Pharmacol Ther 75: P39-P39; doi:10.1016/j.clpt.2003.11.150
Optimal, sparse sampling times of anti-factor XA (anti-XA) activity following subcutaneous enoxaparin administration in patients with chronic kidney disease (CKD)
B. R. Overholser PharmD and K. M. Sowinski PharmD
Clin Pharmacol Ther 75: P40-P40; doi:10.1016/j.clpt.2003.11.151
Application of trial simulation in the design of a clinical study of recombinant factor (RFVIIA) in cirrhotic patients with active varicose bleeding
T. Klitgaard MSc
Clin Pharmacol Ther 75: P40-P40; doi:10.1016/j.clpt.2003.11.152
CYP2D6 poor metabolizers in depressed women of Mexican origin
D. L. Flores MD, D. Flockhart MD and J. Licinio MD
Clin Pharmacol Ther 75: P41-P41; doi:10.1016/j.clpt.2003.11.153
Population pharmacokinetic model of omeprazole following single oral doses in pediatric subjects
J. Li PhD, G. J. Robbie PhD, T. Puchalski PharmD, H. Winter PhD, T. Tzeng PhD, B. Birmingham PhD, J. Zhao MD, PhD, T. Andersson PhD, P. Martin MD and P. Lundborg MD, PhD
Clin Pharmacol Ther 75: P41-P41; doi:10.1016/j.clpt.2003.11.154
Population pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis of CCI-779 in patients with advanced renal cell cancer
J. P. Boni, C. Leister, G. Bender, V. Fitzpatrick, N. Twine, J. Stover, A. Dorner, F. Immermann and M. Burczynski
Clin Pharmacol Ther 75: P41-P41; doi:10.1016/j.clpt.2003.11.155
Application of a map Bayesian method for CYP2E1 phenotyping
T. M. Nicholas MS, M. R. Gastonguay PhD, K. R. Sweeney PhD, T. D. Nolin PharmD, PhD and R. F. Frye PharmD, PhD
Clin Pharmacol Ther 75: P41-P41; doi:10.1016/j.clpt.2003.11.156
Statistical estimation of the minimum drug concentration at the steady state when the assay result is below the lower limit of quantitation
Y. Chiu PhD, D. Burt PhD, B. Hosmane PhD and R. J. Bertz PhD
Clin Pharmacol Ther 75: P42-P42; doi:10.1016/j.clpt.2003.11.157
WAM (Wald's Approximation Method): a user-friendly software program for efficient covariate model building
K. G. Kowalski MS, W. Wang PhD and D. Hermann PharmD
Clin Pharmacol Ther 75: P42-P42; doi:10.1016/j.clpt.2003.11.158
A novel PD model for gatifloxacin (GF) vs. salmonella typhi (ST) in timed kill curves (KC)
O. O. Okusanya PharmD, B. M. Booker PharmD, A. Forrest PharmD, P. F. Smith PharmD, S. M. Bhavnani PharmD and P. G. Ambrose PharmD
Clin Pharmacol Ther 75: P42-P42; doi:10.1016/j.clpt.2003.11.159
A better estimate of lognormal means on pharmacokinetic data
H. Zhi MS and H. Shen PhD
Clin Pharmacol Ther 75: P42-P42; doi:10.1016/j.clpt.2003.11.160
Estimating tumor response rates using shrinkage estimates
S. J. Kathman PhD and M. D. Hale PhD
Clin Pharmacol Ther 75: P43-P43; doi:10.1016/j.clpt.2003.11.161
RBC-cholinesterase (RBC-ACHE) activity is not a reliable marker for low-dose long-term organophosphate exposure (OPE) in rats
G. A. Petroianu MD PhD, M. Newson-Smith, M. Y. Hasan, K. Arafat, M. Kosanovic, S. Nurulain, M. Shafiullah and O. Naseer
Clin Pharmacol Ther 75: P43-P43; doi:10.1016/j.clpt.2003.11.162
Delayed disposition of cocaine in sweat patches and in skin blister: cocaine may migrate from plasma to sweat patches via interstitial fluid
N. Uemura MD, PhD, M. R. Harkey PhD, R. P. Nath MD, G. L. Henderson PhD, J. E. Mendelson MD and R. T. Jones MD
Clin Pharmacol Ther 75: P44-P44; doi:10.1016/j.clpt.2003.11.163
Improvement of hazardous medication ordering practice by physician and nurse education and pharmacist intervention
G. H. Sokol MD, C. Dellagrotta, J. F. Knudsen MD, PhD and L. R. Cantilena Jr MD, PhD
Clin Pharmacol Ther 75: P44-P44; doi:10.1016/j.clpt.2003.11.164
Ephedra and caffeine produce insulin resistance and hypokalemia in healthy subjects
C. A. Haller MD and N. L. Benowitz MD
Clin Pharmacol Ther 75: P44-P44; doi:10.1016/j.clpt.2003.11.165
Hair cortisol - a potential biological marker for chronic stress
J. Klein MSc, T. Karaskov MD, B. Stevens, J. Yamada and G. Koren
Clin Pharmacol Ther 75: P44-P44; doi:10.1016/j.clpt.2003.11.166
Torsades des Pointe (TDP) associated with methadone maintenance therapy (MMT) in a patient with hepatitis-induced cirrhosis
S. R. Tiyyagura MD, S. A. Waldman MD, PhD and W. K. Kraft MD
Clin Pharmacol Ther 75: P45-P45; doi:10.1016/j.clpt.2003.11.167
Platelet serotonin (5-HT) reuptake for biomarking SSRI therapeutics in adolescents
J. M. Perel PhD, D. Axelson MD, G. Rudolph BS, B. Birmaher MD, S. Nuss RN and D. Brent MD
Clin Pharmacol Ther 75: P45-P45; doi:10.1016/j.clpt.2003.11.168
Cytochrome P450 eicosanoids regulate fatty acid metabolism via PPAR|[alpha]|
V. Ng and D. L. Kroetz PhD
Clin Pharmacol Ther 75: P45-P45; doi:10.1016/j.clpt.2003.11.169
Statins decrease levels of the estrogen receptor in human breast cancers
R. J. Hohl MD, PhD and S. L. Roman DO, MS
Clin Pharmacol Ther 75: P45-P45; doi:10.1016/j.clpt.2003.11.170
Soluble guanylyl cyclase is an ATP sensor coupling nitric oxide signaling to cell metabolism
S. R. Tiyyagura MD, I. Ruiz-Stewart PhD, S. Kazerounian PhD, E. Lin, G. M. Pitari MD, PhD, S. Schulz PhD, E. Martin PhD, F. Murad MD, PhD and S. A. Waldman MD, PhD
Clin Pharmacol Ther 75: P46-P46; doi:10.1016/j.clpt.2003.11.171
Maladaptive cardiac remodeling and mortality under mineralocorticoid induced hypertension following KATP channel knockout
G. C. Kane MD, F. O'Coclain MD, D. M. Hodgson MD, S. Reyes, T. Miki MD, S. Seino MD, PhD and A. Terzic MD PhD
Clin Pharmacol Ther 75: P46-P46; doi:10.1016/j.clpt.2003.11.172
Population pharmacokinetic analysis of atomoxetine in pediatric patients
J. Witcher PhD, D. Kurtz MS, M. Heathman MS, J. Sauer PhD and B. Smith PhD
Clin Pharmacol Ther 75: P46-P46; doi:10.1016/j.clpt.2003.11.173
Efficacy, safety and pharmacokinetics of levocetirizine in allergic children aged 1-2 years
N. E. Cranswick MD, M. Fuchs MD and J. Turzikova MD
Clin Pharmacol Ther 75: P46-P46; doi:10.1016/j.clpt.2003.11.174
Tolterodine (TOL) prolonged release (PR) in children aged 11-15 years
D. L. Blowey MD, S. Abdel-Rahman, W. S. Bundrick, R. Jayanthi, P. Reddy, D. Rivas, M. Borin and N. Borgstein
Clin Pharmacol Ther 75: P47-P47; doi:10.1016/j.clpt.2003.11.175
Pharmacokinetics of methotrexate in infants with acute lymphoblastic leukemia
P. Thompson MD, Z. E. Dreyer MD, S. Blaney MD, S. Berg MD, D. Murry PharmD and L. Bomgaars MD
Clin Pharmacol Ther 75: P47-P47; doi:10.1016/j.clpt.2003.11.176
Testing single dose moxifloxacin and ibutilide as positive controls for detecting QTC prolongation in healthy subjects
C. J. Harris PharmD and A. C. Cyr
Clin Pharmacol Ther 75: P47-P47; doi:10.1016/j.clpt.2003.11.177
A definitive study of the effects of PDE-5 inhibitors on cardiac repolarization in middle-age males
B. E. Ilson, B. C. Shaddinger, G. A. Dabiri, B. R. Patel, D. A. Boyle, V. Sethuraman, T. Montague and J. Morganroth
Clin Pharmacol Ther 75: P47-P47; doi:10.1016/j.clpt.2003.11.178
The effect of inflammation on ligand binding and density of L-type calcium and erg K-channels in rat myocardium
S. Sattari PharmD, F. Karimi-Bushehri PhD, M. Weinfeld PhD, W. F. Dryden PhD and F. Jamali PhD
Clin Pharmacol Ther 75: P48-P48; doi:10.1016/j.clpt.2003.11.179
Mitogenic CA2+ entry through ICRAC channels reciprocally regulates the tumor suppressor guanylyl cyclase C (GCC)
G. S. Frick MD, PhD, S. Kazerounian PhD, F. J. Shah MS, M. Madesh PhD, I. Ruiz-Stewart PhD, S. Schulz PhD, G. Hajan|[oacute]|czky MD, PhD, S. A. Waldman MD, PhD and G. M. Pitari MD, PhD
Clin Pharmacol Ther 75: P48-P48; doi:10.1016/j.clpt.2003.11.180
Genetic knockout of KATP channels predisposes to catecholamine-induced proarrhythmogenesis
X. Liu MD, PhD, S. Yamada MD, PhD, F. O'Coclain MD, G. Kane MD, D. Hodgson MD, A. Alexeev PhD, A. Jahangir MD, T. Miki, S. Seino and A. Terzic MD, PhD
Clin Pharmacol Ther 75: P48-P48; doi:10.1016/j.clpt.2003.11.181
Frequency of QT recording and the reliability of QT prolongation assessments
H. Sun PhD, P. Chen MS, J. Hunt BS and H. Malinowski PhD
Clin Pharmacol Ther 75: P48-P48; doi:10.1016/j.clpt.2003.11.182
Gene expression profiles of 4-hydroxy-N-desmethyl-tamoxifen (endoxifen)- and 4-hydroxy-tamoxifen (4OHTAM)-treated human breast cancer cells determined by CDNA microarray analysis
Y. Lim MD, PhD, L. Li PhD, Z. Desta PhD, J. M. Rae PhD, D. A. Flockhart MD, PhD and T. C. Skaar PhD
Clin Pharmacol Ther 75: P49-P49; doi:10.1016/j.clpt.2003.11.183
The effect of homocysteine on the production of inflammatory cytokines
Y. Asanuma MD, PhD, A. Oeser BSc, E. Stanley, A. Shintani PhD and C. M. Stein MD
Clin Pharmacol Ther 75: P49-P49; doi:10.1016/j.clpt.2003.11.184
COX-2 inhibitors and carbonic anhydrase activity
J. F. Knudsen MD, PhD, U. Carlsson PhD, P. Hammarstr|[ouml]|m PhD, G. H. Sokol MD and L. R. Cantilena Jr MD, PhD
Clin Pharmacol Ther 75: P49-P49; doi:10.1016/j.clpt.2003.11.185
The putative tumor suppressor Cdx2 is over-expressed in human colonic adenocarcinomas
M. Witek, J. Park MD, PhD, R. Walters, K. Neilsen, S. Schulz PhD, J. Palazzo MD and S. A. Waldman MD, PhD
Clin Pharmacol Ther 75: P49-P49; doi:10.1016/j.clpt.2003.11.186
Correlation of MCP1 with toxicity in acetaminophen overdose
L. P. James MD, P. Simpson PhD, G. Wasserman MD, H. A. Farrar MD, G. L. Kearns PharmD, PhD and J. A. Hinson PhD, UAMS
Clin Pharmacol Ther 75: P50-P50; doi:10.1016/j.clpt.2003.11.187
Effect of diet on caffeine elimination in healthy infants
M. J. Blake PhD, MD, S. M. Abdel-Rahman PharmD and G. L. Kearns PharmD, PhD
Clin Pharmacol Ther 75: P50-P50; doi:10.1016/j.clpt.2003.11.188
Ontogeny of cytochrome 3A and P-glycoprotein in the human intestine
M. Fakhoury, C. Litalien, Y. Medard, M. Peuchmaur and E. Jacqz-Aigrain
Clin Pharmacol Ther 75: P50-P50; doi:10.1016/j.clpt.2003.11.189
Induction of cytochrome P450 1A by formula: a comparative study between human milk and formula
H. Xu MD, P. Harper PhD, J. Watson-Macdonell RN and S. Ito MD
Clin Pharmacol Ther 75: P50-P50; doi:10.1016/j.clpt.2003.11.190
Effects of human milk and formula on expression of MDR1, MRP2, and CYP3A in the C2BBE1 intestinal cell model
K. Kazuhiro PhD, R. Lee Msc, H. Xu MD, P. Harper PhD and S. Ito MD
Clin Pharmacol Ther 75: P51-P51; doi:10.1016/j.clpt.2003.11.191
Pharmacogenetics of CYP3A7 variability in fetal liver
J. S. Leeder PharmD, PhD, K. A. Marcucci BS, R. Gaedigk PhD, A. Gaedigk PhD and R. E. Pearce PhD
Clin Pharmacol Ther 75: P51-P51; doi:10.1016/j.clpt.2003.11.192
Involvement of the pregnane X receptor in regulation of transporters during inflammation
S. Teng BSc and M. Piquette-Miller PhD
Clin Pharmacol Ther 75: P51-P51; doi:10.1016/j.clpt.2003.11.193
Modulation of adopted nuclear receptors, pregnane X receptor (PXR) and constitutive androstane receptor (CAR), by commonly prescribed chemotherapy agents
A. C. Lockhart MD, W. Lee PhD, A. D. Ingram BA, K. A. Lee BS and R. B. Kim MD
Clin Pharmacol Ther 75: P51-P51; doi:10.1016/j.clpt.2003.11.194
Extensive alternative splicing of cytochrome P4502D6 (CYP2D6) mRNA: explanation for variability among subjects with identical genotypes?
A. Gaedigk MS, PhD, R. Gaedigk MS, PhD, P. K. Rogan PhD and J. S. Leeder PharmD, PhD
Clin Pharmacol Ther 75: P52-P52; doi:10.1016/j.clpt.2003.11.195
Cloning and characterization of putative P-glycoprotein (P-GP) splice variants from human peripheral blood mononuclear cells (PBMCS)
L. W. Chinn, T. D. Giang PharmD, S. J. Johns and D. L. Kroetz PhD
Clin Pharmacol Ther 75: P52-P52; doi:10.1016/j.clpt.2003.11.196
The pharmacokinetics (PK) and pharmacodynamics (PD) of VX-702, a novel, oral P38MAP kinase inhibitor, in healthy volunteers
C. Godfrey PhD, R. Mohanlal MD, E. Merica and E. Ette PhD
Clin Pharmacol Ther 75: P52-P52; doi:10.1016/j.clpt.2003.11.197
A phase I study of recombinant human C1 inhibitor (RHC1INH) in asymptomatic patients with hereditary angioedema (HAE)
M. van Doorn MD, J. Nuijens MD, PhD, R. Schoemaker PhD, K. Burggraaf MD, PhD and A. Cohen MD, PhD
Clin Pharmacol Ther 75: P52-P52; doi:10.1016/j.clpt.2003.11.198
A population pharmacokinetic (PK) analysis of etanercept in patients with juvenile rheumatoid arthritis (JRA)
D. Yim MD, PhD, H. Lee MD, PhD, I. Netorov PhD, H. Zhou PhD, M. Buckwalter PhD and C. C. Peck MD
Clin Pharmacol Ther 75: P53-P53; doi:10.1016/j.clpt.2003.11.199
Pharmacokinetics and pharmacodynamics of a human anti-TNF-alpha monoclonal antibody in patients with rheumatoid arthritis
H. Jang PhD, J. C. Marini PhD, C. Pendley PhD, Q. Jiao MS, S. J. Marciniak Jr. MBA, S. Cohen MD, R. Fleischmann MD, D. E. Everitt MD, H. M. Davis PhD and M. A. Graham PhD
Clin Pharmacol Ther 75: P53-P53; doi:10.1016/j.clpt.2003.11.200
0.8 mg/kg once weekly subcutaneous regimen of etanercept will yield an overlapping steady state time-concentration profile with 0.4 mg/kg twice weekly dosing in pediatric patients with juvenile rheumatoid arthritis (JRA)
H. Lee MD, PhD, D. Yim MD, PhD, I. Nestorov PhD, H. Zhou PhD, M. Buckwalter PhD and C. C. Peck MD
Clin Pharmacol Ther 75: P53-P53; doi:10.1016/j.clpt.2003.11.201
Prediction of radiographic progression in early rheumatoid arthritis (RA) using time-integrated C-reactive protein (TICRP): a population-based approach
H. Zhou PhD and M. Buckwalter BA
Clin Pharmacol Ther 75: P53-P53; doi:10.1016/j.clpt.2003.11.202
Pharmacokinetics (PK) and pharmacodynamics (PD) of SCIO-469, a p38 gamma MAP kinase inhibitor
D. Amakye MBChB, S. Tong MD, C. Ward BSc and W. Beazley BSc
Clin Pharmacol Ther 75: P54-P54; doi:10.1016/j.clpt.2003.11.203
Assessment of the reproducibility of a mental stress test as a first step to its use in drug research
A. van Haarst PhD, S. de Haas MSc, R. Schoemaker PhD, A. Cohen MD, PhD and K. Burggraaf MD, PhD
Clin Pharmacol Ther 75: P54-P54; doi:10.1016/j.clpt.2003.11.204
Human sublingual cell line vs. porcine sublingual tissue - initial permeability studies of beta-blockers
M. S. Chow PharmD, Y. Wang MSc, Z. Zuo PhD and D. Burd MD
Clin Pharmacol Ther 75: P54-P54; doi:10.1016/j.clpt.2003.11.205
Inhibition of uptake-1 activity in the human heart in a hypernoradrenergic state
B. A. Eldadah MD, PhD, K. Pacak MD, PhD, G. Eisenhofer PhD, C. Holmes CMT, I. J. Kopin MD and D. S. Goldstein MD, PhD
Clin Pharmacol Ther 75: P54-P54; doi:10.1016/j.clpt.2003.11.206
Alpha-2C adrenergic receptor (ADRA2C) 322-325 deletion polymorphism and in vivo vascular sensitivity
M. Muszkat MD, G. Sofowora MD, H. Xie MD, PhD, A. J. Wood MD and C. Stein MD
Clin Pharmacol Ther 75: P55-P55; doi:10.1016/j.clpt.2003.11.207
Consideration of beta-1 adrenergic receptor polymorphisms along with traditional risk factors as predictors of prognosis in patients with heart failure
R. P. Rantinella, I. Zineh PharmD, M. L. Potvin, H. N. Yarandi PhD, A. J. Sloan MS, D. F. Pauly MD, PhD and J. A. Johnson PharmD
Clin Pharmacol Ther 75: P55-P55; doi:10.1016/j.clpt.2003.11.208
Blunted vascular reactivity in healthy subjects at risk for type 2 diabetes mellitus
A. Kadirvelu MBBS, N. Heng PharmD, S. Chan MD, FRCP, A. Choy MD, FRCP, M. Mustaffa and C. Lang MD, FRCP, FACC
Clin Pharmacol Ther 75: P55-P55; doi:10.1016/j.clpt.2003.11.209
The chaotic QT interval variabilities on risk assessment trial designs
H. Sun PhD, P. Chen MS, L. Kenna PhD and P. Lee PhD
Clin Pharmacol Ther 75: P55-P55; doi:10.1016/j.clpt.2003.11.210
Sensitivity/reliability of the time-matched baseline subtraction method in assessment of QTc interval prolongation
S. H. Lee PhD, H. Sun PhD, P. Chen MS, S. Doddapaneni PhD, J. Hunt BS and H. Malinowski PhD
Clin Pharmacol Ther 75: P56-P56; doi:10.1016/j.clpt.2003.11.211
Pharmacokinetic and pharmacodynamic profile of icatibant
Y. Perrin MD, M. T. Nguyen MD, P. Rousso MD, T. Buclin MD, B. Rochat PhD, L. Decosterd PhD, M. Appenzeller, F. Jaquet PhD, F. Brunner-Ferber PhD, B. Rosenkranz MD, J. Knolle PhD and J. Biollaz MD
Clin Pharmacol Ther 75: P56-P56; doi:10.1016/j.clpt.2003.11.212
Rating scales for heartburn (HB) studies
S. Korn MD, M. Villani, R. Tipping and J. G. Levine MD
Clin Pharmacol Ther 75: P56-P56; doi:10.1016/j.clpt.2003.11.213
Population pharmacokinetics of rosuvastatin in normal subjects and subjects with dyslipidemia
T. Tzeng PhD, P. Mitchell MS, H. Zhang MS, L. Kung MS, D. Schneck MD and B. K. Birmingham PhD
Clin Pharmacol Ther 75: P56-P56; doi:10.1016/j.clpt.2003.11.214
Icatibant has no impact on renal function in healthy subjects
P. Rousso, M. Nguyen, Y. Perrin, T. Buclin MD, L. A. D|[eacute]|costerd, J. Nussberger, M. Appenzeller, F. Jaquet, F. Brunner-Ferber, B. Rosenkranz, J. Knolle and J. Biollaz
Clin Pharmacol Ther 75: P57-P57; doi:10.1016/j.clpt.2003.11.215
Low membrane protein sulfhydrils but not glucose-6-phosphate dehydrogenase deficiency predict ribavirin-induced hemolysis
S. Russmann MD, I. Grattagliano, V. O. Palmieri, P. Portincasa, F. Bihl, G. Palasciano and B. H. Lauterburg
Clin Pharmacol Ther 75: P57-P57; doi:10.1016/j.clpt.2003.11.216
The absence of intersubject transfer of 17|[beta]|-estradiol gel between dosed and non-dosed post-menopausal women after direct skin-to-skin contact
T. L. ZumBrunnen PharmD, I. Meuwsen MSc, M. H. de Vries PharmD, PhD and J. J. Brennan PhD
Clin Pharmacol Ther 75: P57-P57; doi:10.1016/j.clpt.2003.11.217
Gallbladder volume as a biomarker for the motilin effect in healthy volunteers and patients with functional dyspepsia
A. van Haarst PhD, I. Kamerling PhD, M. de Kam MSc, A. Cohen MD, PhD, A. Masclee MD, PhD and K. Burggraaf MD, PhD
Clin Pharmacol Ther 75: P57-P57; doi:10.1016/j.clpt.2003.11.218
Lack of effect of age and gender on MK-0767 pharmacokinetics in healthy subjects
R. K. Rippley PhD, C. Thach PhD, D. Hreniuk BS, J. L. Miller BS, RN, K. Yan MS, H. Song PhD, K. C. Lasseter MD, K. M. Gottesdiener MD and J. A. Wagner MD, PhD
Clin Pharmacol Ther 75: P58-P58; doi:10.1016/j.clpt.2003.11.219
Pharmacokinetics and bioavailabilty of an ultra low dose estradiol transdermal system in healthy postmenopausal women
N. Poola PhD, A. Uddin PhD, D. Bourg, D. Morrison DO and A. Karara PhD
Clin Pharmacol Ther 75: P58-P58; doi:10.1016/j.clpt.2003.11.220
Effect of injection site on relative bioavailability of exenatide (synthetic exendin-4)
F. Calara PhD, K. Taylor PhD, J. Han MS, M. Aisporna MS, E. Zabala BS, E. Carr BS and M. Fineman BS
Clin Pharmacol Ther 75: P58-P58; doi:10.1016/j.clpt.2003.11.221
Safety profile of long term administration of low dose hydroxyurea in thalassemia intermedia
K. Mousavizadeh PhD, PharmD and M. Karimi MD
Clin Pharmacol Ther 75: P58-P58; doi:10.1016/j.clpt.2003.11.222
Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates
K. Neville MD, R. A. Parise MD, PhD, S. M. Blaney MD, P. Thompson MD, A. Aleksic PhD, M. J. Egorin MD, F. M. Balis MD, L. McGuffey, C. McCully BS and S. L. Berg MD
Clin Pharmacol Ther 75: P59-P59; doi:10.1016/j.clpt.2003.11.223
N-terminal pro-BNP is a possible early biomarker for the cardiac side-effects of anthracyclines
K. Burggraaf MD, PhD, F. Arnold, V. Nickolson MD, S. Osanto MD, PhD and A. Cohen MD, PhD
Clin Pharmacol Ther 75: P59-P59; doi:10.1016/j.clpt.2003.11.224
Effects of age and gender on the pharmacokinetics of lonafarnib (L) following a single oral dose
Y. Zhu MS, P. Statkevich PhD, D. Curtis MS, D. L. Cutler MD, M. Zhang PharmD, W. Richards PhD and V. K. Batra PhD
Clin Pharmacol Ther 75: P59-P59; doi:10.1016/j.clpt.2003.11.225
Pharmacokinetics (PK) of lonafarnib (L), a farnesyl protein transferase inhibitor
Y. Zhu MS, P. Statkevich PhD, D. L. Cutler MD, A. Calzetta, D. Curtis MS and V. K. Batra PhD
Clin Pharmacol Ther 75: P59-P59; doi:10.1016/j.clpt.2003.11.226
The impact of timing of chemotherapy relative to darbepoetin alfa (DA) on DA pharmacokinetics (PK) and hematologic effects
A. C. Heatherington PhD, D. Henry MD, R. Patel MD, N. S. Tchekmedyian MD, R. Berg BS, M. Austin MS, G. Rossi PhD and J. Glaspy MD
Clin Pharmacol Ther 75: P60-P60; doi:10.1016/j.clpt.2003.11.227
Apoptosis in anti-tumor effect of irinotecan is mediated by p53 in human hepatocellular carcinoma cell line
K. Kamio, T. Kumai PhD, N. Mastumoto MD, PhD, Y. Takeba PhD, S. Sekine MD, R. Taniguchi MD and S. Kobayashi MD, PhD
Clin Pharmacol Ther 75: P60-P60; doi:10.1016/j.clpt.2003.11.228
A novel chicken embryo model for the investigation of drugs with antimetastatic properties
D. M. Gvozdjan MD, E. T. Bowden PhD and A. Wellstein MD, PhD
Clin Pharmacol Ther 75: P60-P60; doi:10.1016/j.clpt.2003.11.229
Comparison of genotypic and phenotypic strategies for individualized therapy with the narrow therapeutic drug warfarin
V. Michaud MSc, N. Morin MSc, D. Brouillette MSc, D. Roy MD, L. Verret MSc, N. Noel MSc, I. Taillon MSc, G. O'Hara MD, D. Gossard MD, M. Champagne BSc, M. Vanier MSc and J. Turgeon PhD
Clin Pharmacol Ther 75: P60-P60; doi:10.1016/j.clpt.2003.11.230
Rosiglitazone works synergistically with gemcitabine to induce cell death in pancreas cancer cell lines
A. N. Salesiotis MD, L. Laguinge PhD, S. Ling BSc, J. Marshall MD and J. M. Jessup MD
Clin Pharmacol Ther 75: P61-P61; doi:10.1016/j.clpt.2003.11.231
Beta1-adrenergic receptor polymorphisms and hypertension
A. L. Beitelshees PharmD, L. H. Cavallari PharmD, K. L. Gaston, T. U. Okorochukwu and J. A. Johnson PharmD
Clin Pharmacol Ther 75: P61-P61; doi:10.1016/j.clpt.2003.11.232
The association between the CYP3A5 genotype and blood pressure
H. Ho MD, A. Pinto MD, S. D. Hall PhD, D. A. Flockhart MD, PhD, L. Li PhD, T. Skaar PhD, U. Wagner RN, N. S. Fineberg PhD and M. H. Weinberger MD
Clin Pharmacol Ther 75: P61-P61; doi:10.1016/j.clpt.2003.11.233
The association between CYP3A5 genotype and antihypertensive response
H. Ho MD, S. D. Hall PhD, D. A. Flockhart MD, PhD, L. Li PhD, T. Skaar PhD, P. Cadman MD and D. T. O'Connor MD,
Clin Pharmacol Ther 75: P62-P62; doi:10.1016/j.clpt.2003.11.234
Defining the inhibitory potential of uremic toxins on erythromycin hepatic metabolism
H. Sun MD, PhD, Y. Huang MD, PhD, L. Frassetto MD and L. Benet PhD
Clin Pharmacol Ther 75: P62-P62; doi:10.1016/j.clpt.2003.11.235
A population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of cinacalcet HCL in renal-dialysis patients with secondary hyperparathyroidism (HPT)
B. Wang PhD, T. Ludden PhD, M. Gonzalez BS, P. Rein BS and R. Harris PhD
Clin Pharmacol Ther 75: P62-P62; doi:10.1016/j.clpt.2003.11.236
Effectiveness of monthly IV Iron maintenance regimen for chronic hemodialysis patients
K. Na-Thalang MS, C. Gilmartin PharmD and A. Lau PharmD
Clin Pharmacol Ther 75: P62-P62; doi:10.1016/j.clpt.2003.11.237
Prevalence of cytochrome P450 CYP2C8 polymorphisms in African-Americans (AA) endstage renal disease (ESRD)
A. W. Dreisbach MD, S. Japa PhD, A. B. Gebrekal BS, J. P. Fonseca MD, M. B. Parenti RN, F. M. Farin MD and J. J. Lertora MD, PhD
Clin Pharmacol Ther 75: P63-P63; doi:10.1016/j.clpt.2003.11.238
Pharmacogenetics of loop diuretics
S. V. Vormfelde MD, A. Zirk MD, J. Westermann, M. Torn, F. Tuchen, M. R. Toliat MD and J. Brockm|[ouml]|ller MD
Clin Pharmacol Ther 75: P63-P63; doi:10.1016/j.clpt.2003.11.239
The effect of high and low salt diets on the expression of WNK 4 kinase in the kidneys of sprague dawley rats
H. Mayan, M. Shaharabany PhD, E. Holtzman MD and Z. Farfel MD
Clin Pharmacol Ther 75: P63-P63; doi:10.1016/j.clpt.2003.11.240
MRP4- and MRP5-mediated efflux of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) by microglia
S. Dallas MSc, P. Ronaldson BSc, X. Zhu, L. Schlichter PhD and R. Bendayan PharmD
Clin Pharmacol Ther 75: P64-P64; doi:10.1016/j.clpt.2003.11.241
Lack of effect of chloroquine on pupillary size in man
A. Q. Adigun MD, G. L. Lemma MD, M. Arefayene MSc, Z. Desta PhD, H. Herbert MD, L. Lang PhD and D. A. Flockhart MD, PhD
Clin Pharmacol Ther 75: P64-P64; doi:10.1016/j.clpt.2003.11.242
Pharmacokinetics and pharmacodynamics of intravenous methylene blue in healthy rhesus monkeys
P. Teja-Isavadharm PhD, T. L. Barker MD, MPH, M. Gettayacamin DVM, R. S. Miller MD and C. K. Ohrt MD, MPH
Clin Pharmacol Ther 75: P64-P64; doi:10.1016/j.clpt.2003.11.243
The LOPSAQ study: a pharmacokinetic analysis of a boosted double protease inhibitor (PI)- salvage therapy with saquinavir (SQV) plus lopinavir/ritonavir (LPV/RTV) without reverse transcriptase inhibitors (RTI) in HIV-1 positive adults
N. von Hentig MD, S. Harder MD, C. Stephan MD, B. Dauer MD and S. Staszewski MD
Clin Pharmacol Ther 75: P65-P65; doi:10.1016/j.clpt.2003.11.244
The CRIXILOP cohort study: indinavir plasma exposure is not affected by lopinavir/ritonavir co-administration in a boosted double protease inhibitor (PI)-only therapy regimen
N. von Hentig MD, B. Dauer MD, M. Kurowski MD, S. Staszewski MD and S. Harder MD
Clin Pharmacol Ther 75: P65-P65; doi:10.1016/j.clpt.2003.11.245
The effect of rifaximin on the pharmacokinetics (PK) of single doses of intravenous (IV) and oral (PO) midazolam in healthy volunteers
A. King MD, R. Laurie PharmD, M. Connolly PhD, A. Kamm, H. Boxenbaum PhD, H. Kastrissios PhD and C. Trapnell MD
Clin Pharmacol Ther 75: P66-P66; doi:10.1016/j.clpt.2003.11.246
Sex-based pharmacokinetics of intravenous levofloxacin (LEV) in healthy subjects
B. R. Overholser PharmD, M. B. Kays PharmD, S. Lagvankar DO, M. Goldman MD and K. M. Sowinski PharmD
Clin Pharmacol Ther 75: P66-P66; doi:10.1016/j.clpt.2003.11.247
Evaluation of ethnicity, gender, and OATP-C genotypes as determinants of pravastatin disposition
R. H. Ho MD, W. Lee PhD, G. Mayo RN, G. K. Dresser MD, D. G. Bailey PhD and R. B. Kim MD
Clin Pharmacol Ther 75: P66-P66; doi:10.1016/j.clpt.2003.11.248
Relationship between CYP2C9 genetic polymorphisms and effects of the loop diuretic torasemide
S. V. Vormfelde MD, A. Zirk MD, J. Westermann BS, J. C. Kirchheiner, MD and J. Brockm|[ouml]|ller MD
Clin Pharmacol Ther 75: P66-P66; doi:10.1016/j.clpt.2003.11.249
On the impact of the CYP2D6 ultra-rapid metabolizer genotype on mirtazapine pharmacokinetics
J. Brockm|[ouml]|ller MD, J. Kirchheiner MD, H. Henckel BS, I. Meineke PhD and I. Roots MD
Clin Pharmacol Ther 75: P67-P67; doi:10.1016/j.clpt.2003.11.250
Pharmacokinetics and pharmacogenetics predict the inhibitory effects of tamoxifen on platelet aggregation
Y. Jin MD, B. Ward, A. Bermes, A. M. Storniolo MD, S. Lemler RN, T. Skaar PhD, Z. Desta PhD and D. A. Flockhart MD, PhD
Clin Pharmacol Ther 75: P67-P67; doi:10.1016/j.clpt.2003.11.251
Pharmacokinetics of midazolam in korean healthy subjects with CYP3A4 wild type and |[ast]|18 variant
W. Kang PhD, H. Jung MS, Y. Yoon MD, PhD, K. Liu PhD, I. Cha MD, PhD and J. Shin MD, PhD
Clin Pharmacol Ther 75: P67-P67; doi:10.1016/j.clpt.2003.11.252
C-1584G polymorphism is not the very SNP causing increased CYP2D6 activity of CYP2D6|[ast]|41
S. Lee PhD, H. Jeong MS, S. Yea PhD and J. Shin MD, PhD
Clin Pharmacol Ther 75: P67-P67; doi:10.1016/j.clpt.2003.11.253
Genetic polymorphism of cytochrome P450 2B6 in a Korean population
S. Lee PhD, S. Kim MS, H. Jeong MS, J. Shon MD, Y. Yoon MD, PhD and J. Shin MD, PhD
Clin Pharmacol Ther 75: P68-P68; doi:10.1016/j.clpt.2003.11.254
The mutant a allele function in exon 21 G2677T/A of human MDR1 gene
S. Yi, K. Hong MD, H. Lim MD, J. Chung MD, D. Oh OMD, J. Kim MD, H. Chung, J. Cho PhD, I. Jang MD, PhD and S. Shin MD, PhD
Clin Pharmacol Ther 75: P68-P68; doi:10.1016/j.clpt.2003.11.255
Effect of the sex-related MDR1 gene polymorphisms on fexofenadine disposition
H. Chung, S. Yi, K. Hong MD, H. Lim MD, J. Chung MD, D. Oh OMD, J. Kim MD, J. Cho PhD, I. Jang MD, PhD and S. Shin MD, PhD
Clin Pharmacol Ther 75: P68-P68; doi:10.1016/j.clpt.2003.11.256
Genetic polymorphism of CYP2C9 in a Vietnamese population
K. Kim BS, Y. Sunwoo MD, J. Ryu MD, S. Lee, Y. Yoon MD, PhD, I. Cha MD, PhD and J. Shin MD, PhD
Clin Pharmacol Ther 75: P68-P68; doi:10.1016/j.clpt.2003.11.257
Extensive evaluation of genetic polymorphism of CYP2C19 in a Korean population: interethnic comparison among Asian populations
J. Lee BS, Y. Yoon MD, PhD, H. Jeong MS, S. Lee PhD, K. Liu PhD, W. Kang PhD, I. Cha MD, PhD and J. Shin MD, PhD
Clin Pharmacol Ther 75: P69-P69; doi:10.1016/j.clpt.2003.11.258
When should urine samples for NAT2 phenotyping with caffeine be collected?
A. Jetter MD, M. Kinzig-Schippers PhD, M. Illauer BSc, D. Tomalik-Scharte BSc, F. S|[ouml]|rgel PhD and U. Fuhr MD
Clin Pharmacol Ther 75: P69-P69; doi:10.1016/j.clpt.2003.11.259
Tissue biopsy techniques for gene-expression profiling in clinical pharmacology
M. van Doorn MD, M. Kemme MD, PhD, A. Cohen MD, PhD, E. van Hoogdalem PhD and K. Burggraaf MD, PhD
Clin Pharmacol Ther 75: P69-P69; doi:10.1016/j.clpt.2003.11.260
CYP genotypes influence the effect of tamoxifen therapy on serum lipids
M. I. Rehman MD, K. Lee MD, PhD, A. Bermes BSc, T. Skaar PhD, M. Arefayene, L. Li PhD, V. Stearns MD, D. F. Hayes MD and D. A. Flockhart MD, PhD
Clin Pharmacol Ther 75: P69-P69; doi:10.1016/j.clpt.2003.11.261
The influence of tumor necrosis factor gene polymorphisms on experimental and clinical pain responses in humans
H. Kim DDS, PhD, C. Picco BA, J. Rowan RN, MS, J. Brahim DDS, MS and R. Dionne DDS, PhD
Clin Pharmacol Ther 75: P70-P70; doi:10.1016/j.clpt.2003.11.262
A common polymorphism in the adenylyl cyclase type 9 (AC9) gene does not alter vascular responses to isoproterenol
H. Xie MD, PhD, R. Landau MD, V. Dishy MD, G. G. Sofowora MD, R. M. Smiley MD, PhD, R. B. Kim MD, A. J. Wood MD and C. M. Stein MD
Clin Pharmacol Ther 75: P70-P70; doi:10.1016/j.clpt.2003.11.263
Genetic polymorphisms of the CYP3A5 and MDR-1 genes and effect of clarithromycin (CLAR) on midazolam (MDZ) pharmacokinetics
Y. Wang PhD, H. Ho MD, J. Renbarger MD, J. C. Gorski PhD and S. D. Hall PhD
Clin Pharmacol Ther 75: P70-P70; doi:10.1016/j.clpt.2003.11.264
SLV 308: plasma levels of effective doses in MPTP-treated marmosets in comparison with plasma levels and D2 receptor occupancy (PET) in humans
M. H. De Vries PhD, PharmD, M. B. Hesselink PhD, A. A. Winsemius MSc, P. Jenner PhD, L. Johnston MSc and S. Salvage PhD
Clin Pharmacol Ther 75: P70-P70; doi:10.1016/j.clpt.2003.11.265
The potential for clinically significant drug-drug interactions in patients receiving CYP 2D6 model substrate/drugs and fluoxetine/paroxetine or sertraline
S. H. Preskorn MD, R. Shah MD, B. Silkey ScM, M. Neff PharmD, A. Golbeck PhD and J. Choi RPh, PriVia
Clin Pharmacol Ther 75: P71-P71; doi:10.1016/j.clpt.2003.11.266
Effects of low-dose naltrexone on analgesia produced by hydrocodone
L. R. Cantilena Jr MD, PhD, C. Wright IV MD, MPH, J. C. Miller PhD and J. C. Messina Jr PharmD
Clin Pharmacol Ther 75: P71-P71; doi:10.1016/j.clpt.2003.11.267
Dose-response effects of low-dose naltrexone on the analgesia produced by hydrocodone
L. R. Cantilena MD, PhD, M. C. Lenart PharmD, J. C. Miller PhD and J. C. Messina Jr PharmD
Clin Pharmacol Ther 75: P71-P71; doi:10.1016/j.clpt.2003.11.268
Cardiovascular effects of intranasal L-methamphetamine
R. P. Nath MD, D. McGlothlin MD, N. Uemura MD, PhD, E. Fernandez MD, R. T. Jones MD and J. E. Mendelson MD
Clin Pharmacol Ther 75: P71-P71; doi:10.1016/j.clpt.2003.11.269
Use of salvia divinorum, an unscheduled hallucinogenic plant: a web-based survey of 500 users
M. J. Baggott BA, E. Erowid, F. Erowid and J. E. Mendelson MD
Clin Pharmacol Ther 75: P72-P72; doi:10.1016/j.clpt.2003.11.270
Oral ketamine as a positive control in abuse liability studies
M. K. Romach MSc, MD, E. M. Sellers MD, PhD, H. L. Kaplan PhD, L. C. Fernandes MSc, J. Oldenhof PhD and S. McDonald PhD
Clin Pharmacol Ther 75: P72-P72; doi:10.1016/j.clpt.2003.11.271
Comparative American and Japanese tobacco smoke uptake parameters after overnight tobacco deprivation
E. F. Domino MD, C. Kadoya MD, PhD, S. Matsuoka MD, L. Ni MS and K. Fedewa
Clin Pharmacol Ther 75: P72-P72; doi:10.1016/j.clpt.2003.11.272
The relation between total and free plasma concentrations of nucleoside reverse transcriptase inhibitors in HIV-infected children
N. Y. Rakhmanina MD, J. N. van den Anker MD, PhD, J. Sever MD, H. Spiegel MD, PhD and S. Soldin PhD
Clin Pharmacol Ther 75: P72-P72; doi:10.1016/j.clpt.2003.11.273
Is lack of morning sickness teratogenic|[quest]| a prospective controlled study
R. R. Boskovic MD
Clin Pharmacol Ther 75: P73-P73; doi:10.1016/j.clpt.2003.11.274
Can saliva be used for therapeutic drug monitoring of protease inhibitors in HIV-infected children?
N. Y. Rakhmanina MD, J. N. van den Anker MD, PhD, J. Sever MD, H. Spiegel MD, PhD and S. L. Soldin PhD
Clin Pharmacol Ther 75: P73-P73; doi:10.1016/j.clpt.2003.11.275
Pharmacokinetics of rofecoxib in children
D. J. Edwards PharmD, R. P. Prescilla MD, D. A. Fratarelli MD, D. Haritos MD and J. V. Aranda MD, PhD,
Clin Pharmacol Ther 75: P73-P73; doi:10.1016/j.clpt.2003.11.276
Immunohistochemical localisation and mRNA quantification of P-gp in human term placentas - no impact of corticosteroid administration for preterm labor
R. Serreau, M. Fakhoury, G. Bonihay, Y. Medard, M. Peuchmaur, A. Mokhdad, J. Oury and E. Jacqz-Aigrain
Clin Pharmacol Ther 75: P73-P73; doi:10.1016/j.clpt.2003.11.277
Neurodevelopment in children exposed in utero to cyclosporine and azathioprine following maternal renal transplant: preliminary results
I. Nulman MD, M. Sgro MD, M. Barrera PhD, D. Chitayat MD and G. Koren MD
Clin Pharmacol Ther 75: P74-P74; doi:10.1016/j.clpt.2003.11.278
Pharmacokinetics of acetaminophen rectal suppositories in infants post cardiovascular surgery
A. Torres MD, J. F. Graumlich MD, K. M. Skender CPNP, J. D. Wohrley MD and D. M. Geiss MD
Clin Pharmacol Ther 75: P74-P74; doi:10.1016/j.clpt.2003.11.279
Double-blind, placebo-controlled comparison of Auralgan and Americaine for the treatment of otalgia associated with Otitis Media in children
P. D. Walson MD, S. Wason MD, MBA, T. McClain RN, CPNP, T. Xie PhD, D. Van Ginkel MD and R. K. Irvin MD
Clin Pharmacol Ther 75: P74-P74; doi:10.1016/j.clpt.2003.11.280
Application of Monte Carlo simulation to the PK/PD evaluation of Gatifloxacin (GAT) against streptococcus pneumoniae for the treatment of Otitis Media in children
C. D. Costanzo, B. Cirincione, P. G. Ambrose PharmD and C. M. Rubino PharmD
Clin Pharmacol Ther 75: P74-P74; doi:10.1016/j.clpt.2003.11.281
Pregnancy outcome following gestational exposure to sibutramine: a prospective comparative study
M. Sarkar, L. Bonari, K. Mckenna and A. Einarson
Clin Pharmacol Ther 75: P75-P75; doi:10.1016/j.clpt.2003.11.282
Pregnancy outcome following gestational exposure to Azithromycin: a prospective controlled study
M. Sarkar, C. Woodland, N. Pinto, J. Perstein and G. Koren MD
Clin Pharmacol Ther 75: P75-P75; doi:10.1016/j.clpt.2003.11.283
Exposure-response relationship in adults and children for pediatric dose adjustment
A. J. James MS, H. Sun PhD, A. Parekh PhD, S. Doddapaneni PhD, H. Zhao PhD, P. Lee PhD, J. Hunt BS, H. Malinowski PhD, S. Huang PhD and L. Lesko PhD
Clin Pharmacol Ther 75: P75-P75; doi:10.1016/j.clpt.2003.11.284
Relief of MMR vaccination pain using topical 4% amethocaine
L. O'Brien, A. Taddio, M. Ipp, M. Goldbach and G. Koren
Clin Pharmacol Ther 75: P75-P75; doi:10.1016/j.clpt.2003.11.285
Ability of medication adherence, knowledge and skills to predict emergency department visits in older adults with heart failure
C. J. Hope PharmD, MS, J. Wu MS, W. Tu PhD and M. D. Murray PharmD, MPH,
Clin Pharmacol Ther 75: P76-P76; doi:10.1016/j.clpt.2003.11.286
Peri-operative corticosteroids to prevent iatrogenic adrenal insufficiency: are the doses used too high?
K. B. Zarnke MD, G. Dresser MD, R. Moor, P. Colquhoun MD, B. Taylor MD, B. Larocque MD, G. Sue-A-Quan MD, K. Gilbert MD, C. Bycraft, J. Martin PharmD, N. Badner MD, C. McDonald MD, T. Paul MD and J. L. Mahon MD
Clin Pharmacol Ther 75: P76-P76; doi:10.1016/j.clpt.2003.11.287
Health literacy predicts medication adherence
M. D. Murray PharmD, MPH, J. Wu MS, W. Tu PhD, D. O. Clark PhD, M. Weiner MD, MPH, D. G. Morrow PhD and D. C. Brater MD
Clin Pharmacol Ther 75: P76-P76; doi:10.1016/j.clpt.2003.11.288
Use of electronic adherence with PK parameters to predict outcomes of older adult heart failure patients. FREE
W. Tu PhD, J. Li PhD, A. Morris PharmD, J. Wu MS and M. D. Murray PharmD, MPH
Clin Pharmacol Ther 75: P76-P76; doi:10.1016/j.clpt.2003.11.289
Data mining analysis of psychosis with mefloquine and other antimalarial drugs
T. S. Coster MD and A. Szarfman MD, PhD
Clin Pharmacol Ther 75: P77-P77; doi:10.1016/j.clpt.2003.11.290
Correlation between the CYP3A-mediated oral clearances of alprazolam, midazolam and triazolam
A. L. Masica MD, G. Mayo RN and G. R. Wilkinson PhD, DSc
Clin Pharmacol Ther 75: P77-P77; doi:10.1016/j.clpt.2003.11.291
Cefixime (CFX) enables higher plasma exposures of SN-38 to be achieved in pediatric patients receiving oral irinotecan (IRN)
K. R. Crews PharmD, C. F. Stewart PharmD, J. C. Panetta PhD, P. J. Houghton PhD, V. M. Santana MD and W. L. Furman MD
Clin Pharmacol Ther 75: P77-P77; doi:10.1016/j.clpt.2003.11.292
The effect of orange juice on the pharmacokinetics of the 3-hydroxy-3-methylglutaryl COA (HMG-COA) reductase inhibitor pravastatin
Y. Koitabashi MD, T. Kumai PhD, N. Matsumoto MD, PhD, K. Kamio MD, R. Taniguchi MD, S. Sekine MD and S. Kobayashi MD, PhD
Clin Pharmacol Ther 75: P77-P77; doi:10.1016/j.clpt.2003.11.293
No clinically significant interactions between the oral direct thrombin inhibitor ximelagatran and amiodarone, atorvastatin, or digoxin
H. Dorani MSc, K. Sch|[uuml]|tzer MD, M. Wollbratt MSc, T. C. Sarich PhD, U. G. Eriksson PhD, R. Teng PhD, L. Ohlsson MSc, E. Kessler MSc, U. Wall MD, I. Kalies PhD and J. E. Hamer MSc
Clin Pharmacol Ther 75: P78-P78; doi:10.1016/j.clpt.2003.11.294
Effect of erythromycin on the pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran and its active form melagatran
H. Dorani MSc, K. Sch|[uuml]|tzer MD, T. C. Sarich PhD, U. Wall MD, L. Ohlsson MSc and U. G. Eriksson PhD
Clin Pharmacol Ther 75: P78-P78; doi:10.1016/j.clpt.2003.11.295
Development of a pharmacokinetic pharmacodynamic (PKPD) model to predict onset of hemolytic anemia in (PEG)interferon/ribavirin treated hepatitis|[ndash]|C virus (HCV)-infected patients
B. Agoram PhD, R. Marino BS, S. George MD, N. Lam PharmD and A. Heatherington PhD
Clin Pharmacol Ther 75: P78-P78; doi:10.1016/j.clpt.2003.11.296
Lack of effect of aprepitant (APR) on the pharmacokinetics (PK) and safety of palonosetron (PALO)
A. K. Shah PhD, S. C. Gallagher MS, L. Latimer MS, M. T. Cullen MD and T. L. Hunt MD, PhD
Clin Pharmacol Ther 75: P78-P78; doi:10.1016/j.clpt.2003.11.299
Pharmacokinetic study on the interaction between cabergoline and clarithromycin in healthy volunteers and patients with parkinson's disease
M. Nomoto MD, PhD, T. Nomura MD, PhD, A. Nakatsuka, M. Nagai MD, PhD and Y. Yabe MD
Clin Pharmacol Ther 75: P79-P79; doi:10.1016/j.clpt.2003.11.300
Evaluation of herbal products as potential inhibitors of MDR1
G. K. Dresser MD, W. McDonald BSc, R. B. Kim MD and D. G. Bailey PhD
Clin Pharmacol Ther 75: P79-P79; doi:10.1016/j.clpt.2003.11.301
Metabolite patterns measured during repeated dosing of acetaminophen (APAP) At 4, 6, and 8 g/day in healthy adults
C. K. Gelotte PhD, J. F. Auiler MS, J. M. Lynch MD, A. R. Temple MD, J. T. Slattery PhD and D. L. Bowen MD
Clin Pharmacol Ther 75: P79-P79; doi:10.1016/j.clpt.2003.11.302
Effect of R411, a dual |[alpha]|4/|[beta]|1-|[alpha]|4/|[beta]|7 Integrin antagonist being developed for asthma, on the activities of the major drug metabolizing enzymes after oral administration in healthy subjects
R. Abbas PhD, Y. Hijazi, J. Tang, L. Renzetti, A. Rames and H. Welker
Clin Pharmacol Ther 75: P79-P79; doi:10.1016/j.clpt.2003.11.303
No effect of garlic extract on saquinavir kinetics and hepatic CYP3A4 function measured by the erythromycin breath test
H. Jacek MD, K. M. Rentsch PhD, H. C. Steinert MD, C. Pauli-Magnus MD, P. J. Meier MD and K. Fattinger MD
Clin Pharmacol Ther 75: P80-P80; doi:10.1016/j.clpt.2003.11.304
A herb-drug interactions through evaluating cytochrome P450 phenotypic ratios after multiple administration of herbal supplements
D. Oh OMD, J. Cho PhD, S. Yi MS, H. Lim MD, J. Chung MD, J. Kim MD, H. Chung, S. Shin MD, PhD and I. Jang MD, PhD
Clin Pharmacol Ther 75: P80-P80; doi:10.1016/j.clpt.2003.11.305
PK/PD modelling of reversal of neuromuscular blockade by a chemically optimised cyclodextrin
B. A. Ploeger PhD, PharmD, G. Ruigt and M. Danhof PhD, PharmD
Clin Pharmacol Ther 75: P80-P80; doi:10.1016/j.clpt.2003.11.306
Absorption model based on transport physics theory applied to paracetamol
J. I. Freijer PhD, T. M. Post PharmD, B. A. Ploeger PhD, PharmD, J. DeJongh PhD and M. Danhof PhD, PharmD
Clin Pharmacol Ther 75: P80-P80; doi:10.1016/j.clpt.2003.11.307
Improved prediction of drug interactions using in vivo Ki
R. E. Kimura MD, Y. C. Chen MD, V. Jiyamapa-Sherna MS, M. A. Hamman BS, S. D. Hall PhD and R. E. Galinsky PharmD
Clin Pharmacol Ther 75: P81-P81; doi:10.1016/j.clpt.2003.11.308
Miosis following intravenous and oral alfentanil as a noninvasive probe for hepatic and first-pass CYP3A activity
E. D. Kharasch MD, PhD, A. Walker BS, C. Hoffer CCRC and P. Sheffels BS
Clin Pharmacol Ther 75: P81-P81; doi:10.1016/j.clpt.2003.11.309
Sensitivity of intravenous and oral alfentanil miosis as a noninvasive probe for hepatic and first-pass CYP3A activity
E. D. Kharasch MD, PhD, A. Walker BS, C. Hoffer CCRC and P. Sheffels BS
Clin Pharmacol Ther 75: P81-P81; doi:10.1016/j.clpt.2003.11.310
Impact of CYP3A haplotypes on alprazolam kinetics with and without rifampicin induction
M. Goldammer, J. Kirchheiner, S. Bauer, W. Terhalle, C. Meisel, I. Roots and J. Brockm|[ouml]|ller
Clin Pharmacol Ther 75: P81-P81; doi:10.1016/j.clpt.2003.11.311
Population pharmacokinetics of troxacitabine
C. K. Lee PharmD, MPH, E. K. Rowinsky MD, F. Giles MD, M. Moore MD, E. Chu MD, M. Hidalgo MD, E. Capparelli PharmD, J. Jolivet MD and S. D. Baker PharmD
Clin Pharmacol Ther 75: P82-P82; doi:10.1016/j.clpt.2003.11.312
Drug-disease interaction:effect of rheumatoid arthritis (RA) on the pharmacodynamics (PD) and pharmacokinetics (PK) of AT1 receptor antagonists
N. M. Daneshtalab PhD candidate, R. Z. Lewanczuk MD, PhD, A. S. Russell MBChB, MA, FRCP and F. Jamali PhD
Clin Pharmacol Ther 75: P82-P82; doi:10.1016/j.clpt.2003.11.313
Dextromethorphan to dextrorphan urinary metabolic ratio not sensitive enough to assess modest changes in CYP2D6 activity
J. C. Gorski PhD, L. Li PhD, M. A. Hamman BS and S. D. Hall PhD
Clin Pharmacol Ther 75: P82-P82; doi:10.1016/j.clpt.2003.11.314
Effect of co-administration of nelfinavir and covariates on the pharmacokinetics of indinavir in ACTG 388 trial
L. Labb|[eacute]| PhD, G. Morse PharmD, M. A. Fischl MD, J. Feinberg MD, A. Collier MD, R. DiCenzo PharmD and L. B. Sheiner MD
Clin Pharmacol Ther 75: P82-P82; doi:10.1016/j.clpt.2003.11.315
Mechanism-based inhibition of CYP3A4 and CYP3A5 by seven inhibitors
K. C. Patki, L. L. von Moltke MD and D. J. Greenblatt MD
Clin Pharmacol Ther 75: P83-P83; doi:10.1016/j.clpt.2003.11.316
Traditional aqueous kava extracts inhibit CYP4501A2 in humans
S. Russmann MD, Y. Barguil, M. Wenk, R. Theurillat, P. Cabalion, E. Choblet, K. Rentsch and B. H. Lauterburg
Clin Pharmacol Ther 75: P83-P83; doi:10.1016/j.clpt.2003.11.317
A population pharmacokinetic model for penciclovir in human eye and plasma
F. Schenkel, E. Baglivo MD, M. Gex-Fabry, Y. Daali PharmD, M. Kondo Ostreicher MD and P. Dayer Prof
Clin Pharmacol Ther 75: P83-P83; doi:10.1016/j.clpt.2003.11.318
An open label bioequivalence study of oral saquinavir (RO 31-8959) using a stable isotope formulation of saquinavir as an |[ldquo]|in vivo|[rdquo]| internal standard
T. Peluso MBBS, DCPSA, T. G. Mant BSc, FRCP, FFPM, D. M. Amin MRCGP, DCPSA and G. R. McClelland PhD, MIBiol
Clin Pharmacol Ther 75: P83-P83; doi:10.1016/j.clpt.2003.11.319
Role of CYP3A enzymes in fluticasone biotransformation
R. E. Pearce PhD, G. L. Kearns PharmD, PhD and J. S. Leeder PharmD, PhD
Clin Pharmacol Ther 75: P84-P84; doi:10.1016/j.clpt.2003.11.320
Pharmacokinetics of high doses of cyanocobalamin administered by i.v. injection in healthy volunteers
A. A. Nava-Ocampo MD, G. Koren MD, A. Pastrak MD, PhD and T. Cruz PhD
Clin Pharmacol Ther 75: P84-P84; doi:10.1016/j.clpt.2003.11.321
Population pharmacokinetics of nelfinavir (NFV) and its metabolite M8 when administered with ritonavir (RTV)
V. Cosson PharmD, PhD, E. Fuseau PharmD, PhD and B. Kaeser PhD
Clin Pharmacol Ther 75: P84-P84; doi:10.1016/j.clpt.2003.11.322
PK modeling and simulations of an anti IL-6 MAB in patients with renal cell carcinoma
Q. Jiao MS, H. Jang PhD, U. Prabhakar PhD, J. Ford BS, B. Miller PhD, H. M. Davis PhD and M. A. Graham PhD
Clin Pharmacol Ther 75: P84-P84; doi:10.1016/j.clpt.2003.11.323
In-vitro characterization of the metabolism of prochlorperazine
J. M. Collins PharmD, A. L. Finn PharmD, R. D. Voyksner PhD and C. M. Lindley PharmD
Clin Pharmacol Ther 75: P85-P85; doi:10.1016/j.clpt.2003.11.324
Role of CYP3A4 and CYP2B6 in the in vitro N-demethylation of meperidine
J. Ramirez MS, F. Innocenti MD, D. A. Flockhart MD, PhD, R. Santucci MD and M. J. Ratain MD
Clin Pharmacol Ther 75: P85-P85; doi:10.1016/j.clpt.2003.11.325
Effect of food restriction on UDP-glucuronosyltransferase (UGT) enzymes in liver
C. Yu BS, J. K. Ritter PhD, R. J. Krieg PhD, B. Rege PhD, H. T. Karnes PhD and M. A. Sarkar PhD
Clin Pharmacol Ther 75: P85-P85; doi:10.1016/j.clpt.2003.11.326
Effect of chronic renal failure on UDP-glucuronosyltransferase (UGT) enzymes in liver and kidney
C. Yu BS, R. J. Krieg PhD, J. K. Ritter PhD, H. T. Karnes PhD and M. A. Sarkar PhD
Clin Pharmacol Ther 75: P86-P86; doi:10.1016/j.clpt.2003.11.327
In vitro glucuronidation of ABT-751, a novel anticancer agent
F. Innocenti MD, S. Mirkov MS, J. Ramirez MS, L. Cook MS, K. Meek MT, D. Katz PhD and M. J. Ratain MD
Clin Pharmacol Ther 75: P86-P86; doi:10.1016/j.clpt.2003.11.328
The intestine is the major site of interaction between midazolam and verapamil
Y. Wang PhD, Y. Jin MD, J. C. Gorski PhD and S. D. Hall PhD
Clin Pharmacol Ther 75: P86-P86; doi:10.1016/j.clpt.2003.11.329
DA-8159-phase I studies to investigate the safety and pharmacokinetics in healthy male caucasian subjects
D. Amakye MBChB, J. Ward BSc, S. Bryson and K. Han
Clin Pharmacol Ther 75: P86-P86; doi:10.1016/j.clpt.2003.11.330
Differential modulation of CACO-2 mediated transport of rhodamine-123 by 17-beta estradiol, progesterone and testosterone
K. Bertelsen, L. Moltke and D. Greenblatt
Clin Pharmacol Ther 75: P87-P87; doi:10.1016/j.clpt.2003.11.331
The effect of oral pyridostigmine bromide on the recovery of whole blood cholinesterase activity following ex vivo exposure to soman
M. A. Riel DO, COL, MC, R. K. Gordon PhD, J. R. Haigh, G. E. Garcia PhD, C. R. Clark, D. E. Lenz PhD, R. E. Clawson PhD and R. P. Brueckner MD, COL, MC
Clin Pharmacol Ther 75: P87-P87; doi:10.1016/j.clpt.2003.11.332
Absence of P450 effect with a novel phospholipid emulsion (GR270773)
O. J. Naderer PharmD, D. Melich and J. L. Woolley PhD
Clin Pharmacol Ther 75: P87-P87; doi:10.1016/j.clpt.2003.11.333
Randomized dose ranging trials; assessment of statistical power for various design and analysis strategies
A. Grahnen PhD, K. Karlsson MSc, M. O. Karlsson PhD and N. E. Jonsson PhD
Clin Pharmacol Ther 75: P87-P87; doi:10.1016/j.clpt.2003.11.334
A population pharmacokinetic (POP PK) analysis of ritonavir (RTV) in human immunodeficiency virus-infected patients enrolled in ACTG359
M. Levi PhD, R. C. Brundage PharmD, PhD, C. V. Fletcher PharmD and L. B. Sheiner MD
Clin Pharmacol Ther 75: P88-P88; doi:10.1016/j.clpt.2003.11.335
Concentration-QTC modeling in healthy volunteers (HV) and in subjects with major depressive disorder (MDD) for a novel antidepressant candidate
M. A. Gibbs PhD, M. R. Gastonguay PhD, K. R. Sweeney PhD, P. Ravva MS, T. J. Taylor MS, R. M. Berman MD, P. Gray PharmD and L. J. Benincosa PhD, Pfizer
Clin Pharmacol Ther 75: P88-P88; doi:10.1016/j.clpt.2003.11.336
The determination of the efficiency of first time-in-human study designs
H. Chu PhD, J. Zha PhD, A. Roy PhD and E. I. Ette PhD
Clin Pharmacol Ther 75: P88-P88; doi:10.1016/j.clpt.2003.11.337
Nonlinear binding models suggest that ABCIXIMAB (AB) Pharmacokinetics (PK) and pharmacodynamics (PD) are target-mediated
D. E. Mager PharmD, PhD, M. A. Mascelli PhD, N. S. Kleiman MD, D. J. Fitzgerald MD and D. R. Abernethy MD, PhD
Clin Pharmacol Ther 75: P88-P88; doi:10.1016/j.clpt.2003.11.338
PK/PD modeling of QTC duration for vardenafil & sildenafil in healthy volunteers
B. R. Patel PhD, D. A. Boyle PharmD, K. A. Diringer BS, B. E. Ilson MD, B. C. Shaddinger PharmD and T. H. Montague MS
Clin Pharmacol Ther 75: P89-P89; doi:10.1016/j.clpt.2003.11.339
Population pharmacokinetic analysis of enfuvirtide in HIV-1 infected patients
K. Nieforth PharmD, D. Mould PhD, X. Zhang PhD, M. Salgo MD, PhD and I. Patel PhD
Clin Pharmacol Ther 75: P89-P89; doi:10.1016/j.clpt.2003.11.340
The relative importance of between subject correlation of clearance (CL) and volume of distribution (V) compared with correlation of estimation error when applied to pharmacokinetic (PK) simulation
C. E. Garnett PharmD and N. H. Holford MBChB, FRACP
Clin Pharmacol Ther 75: P89-P89; doi:10.1016/j.clpt.2003.11.341
Pharmacokinetics (PK), pharmacodynamics (PD) and GPIIB/IIIA receptor blockade of ABCIXIMAB in stable angina pectoris patients
A. A. Fasanmade PhD, E. Barnathan MD, M. Graham PhD, C. Wagner PhD, H. Davis PhD and R. Jordan PhD
Clin Pharmacol Ther 75: P89-P89; doi:10.1016/j.clpt.2003.11.342
A markov model for the effect of covariates including drug adherence on longitudinal viral response in hiv patients
L. Labb|[eacute]| PhD, S. M. Hammer MD, J. W. Mellors MD, S. Rosenkranz PhD and L. B. Sheiner MD
Clin Pharmacol Ther 75: P90-P90; doi:10.1016/j.clpt.2003.11.343
Disposition of chlorpromazine in Korean healthy subjects with CYP2D6 wild type and |[ast]|10B mutation
Y. E. Sunwoo MD, J. Ryu MD, H. Jung MS, W. Kang PhD, K. Liu PhD, Y. Yoon MD, PhD, S. Lee PhD and J. Shin
Clin Pharmacol Ther 75: P90-P90; doi:10.1016/j.clpt.2003.11.344
Population exposure response analysis of pregabalin in patients with generalized anxiety disorder (GAD)
P. A. Lockwood MS, K. G. Kowalski MS and B. W. Corrigan PhD
Clin Pharmacol Ther 75: P90-P90; doi:10.1016/j.clpt.2003.11.345
A systematic approach to identifying and modeling the source of pharmacokinetic (PK) non-linearity
N. S. Berry PharmD, D. Yim MD, PhD, C. C. Peck MD, D. L. Weiner PhD and H. Lee MD, PhD
Clin Pharmacol Ther 75: P90-P90; doi:10.1016/j.clpt.2003.11.346
A population pharmacokinetic model for bevacizumab
J. Lu, J. Gaudreault PhD, W. Novotny MD, B. Lum PharmD and R. Bruno PhD
Clin Pharmacol Ther 75: P91-P91; doi:10.1016/j.clpt.2003.11.347
Population pharmacokinetic modeling and simulation of intravenous and oral midazolam
C. S. Ernest II BS, S. D. Hall PhD and J. Y. Chien PhD
Clin Pharmacol Ther 75: P91-P91; doi:10.1016/j.clpt.2003.11.348
A bivariate confidence interval approach to calculate drug interaction and bioequivalence study power
J. Y. Chien PhD and G. J. Weerakkody PhD
Clin Pharmacol Ther 75: P91-P91; doi:10.1016/j.clpt.2003.11.349
Pharmacology learning strategies for an integrated medical school curriculum
K. L. Franson PharmD, E. A. Dubois PhD, J. M. van Gerven MD, PhD and A. F. Cohen MD, PhD
Clin Pharmacol Ther 75: P91-P91; doi:10.1016/j.clpt.2003.11.350
Assessment of student & physician provision of therapeutic information in the POMR format
K. L. Franson PharmD, G. Duijzer MD, A. F. Cohen MD, PhD and J. Burggraaf MD, PhD
Clin Pharmacol Ther 75: P92-P92; doi:10.1016/j.clpt.2003.11.351
Critical evaluation of handheld electronic prescribing guides for physicians
F. D. Min MD, B. Smyth MD, N. Berry PharmD, H. Lee MD, PhD and B. C. Knollmann MD, PhD
Clin Pharmacol Ther 75: P92-P92; doi:10.1016/j.clpt.2003.11.352
Clinical usage patterns of interferon therapies in the treatment of hepatitis C (HCV)
C. B. Hare MD, J. J. Loveland MA, A. Chu MA, V. Gotz MS, B. J. Steffen MD and J. A. Morris MD
Clin Pharmacol Ther 75: P93-P93; doi:10.1016/j.clpt.2003.11.353
Identification of single nucleotide polymorphisms in the multidrug resistance-associated protein 4 (MRP4)
C. Marzolini PhD, B. F. Leake BSc and R. B. Kim MD
Clin Pharmacol Ther 75: P93-P93; doi:10.1016/j.clpt.2003.11.354
Identification of nonsynonomous polymorphisms of human organic anion transporting polypeptide-A (OATP-A) associated with altered transport activity
W. Lee PhD, L. H. Smith PhD, G. Gervasini PhD, B. F. Leake BS and R. B. Kim MD
Clin Pharmacol Ther 75: P93-P93; doi:10.1016/j.clpt.2003.11.355
Identification and functional characterization of variants of the human organic anion transporter, OAT3 (SLC22A8)
L. Mangravite PhD, A. Erdman MD and K. M. Giacomini PhD
Clin Pharmacol Ther 75: P93-P93; doi:10.1016/j.clpt.2003.11.356
Pharmacogenetic meta-analysis suggests that atrasentan is an organic anion transport protein C substrate
D. A. Katz PhD, D. R. Grimm PhD, R. Carr PhD, H. Xiong PhD, R. Holley-Shanks MS, T. Mueller MS and A. Allen MD
Clin Pharmacol Ther 75: P94-P94; doi:10.1016/j.clpt.2003.11.357
BSEP and MDR3 sequence diversity and haplotype structure in primary sclerosing cholangitis, primary biliary cirrhosis and intrahepatic cholestasis of pregnancy
C. Pauli-Magnus MD, R. Kerb MD, T. Zodan-Marin MD, T. Lang PhD, K. Fattinger MD, G. A. Kullak-Ublick MD, U. Beuers MD and P. J. Meier MD
Clin Pharmacol Ther 75: P94-P94; doi:10.1016/j.clpt.2003.11.358
Effect of CYP2D6 phenotype and metoprolol pharmacokinetics on adverse effects
A. L. Beitelshees PharmD, I. Zineh PharmD, A. Gaedigk PhD, J. S. Leeder PharmD, PhD, J. R. Walker PharmD, K. Eberst, B. S. Timmerbeil, M. Lobmeyer, D. F. Pauly MD, PhD and J. A. Johnson PharmD
Clin Pharmacol Ther 75: P94-P94; doi:10.1016/j.clpt.2003.11.359
A novel functional genetic variant of CYP2J2 in a Korean population
J. Ryu MD, H. Jung MS, K. Liu PhD, S. Lee PhD, I. Cha MD, PhD and J. Shin MD, PhD
Clin Pharmacol Ther 75: P94-P94; doi:10.1016/j.clpt.2003.11.360
Human phenylethanolamine N-methyltransferase (PNMT) pharmacogenetics: gene resequencing and functional genomic studies
Y. Ji, O. E. Salavaggione MD, A. A. Adjei PhD, B. A. Thomae, B. Eckloff, E. D. Wieben PhD and R. M. Weinshilboum MD
Clin Pharmacol Ther 75: P95-P95; doi:10.1016/j.clpt.2003.11.361
Association of |[beta]|2-adrenergic receptor (|[beta]|2AR) haplotype and hypertension in African Americans and Caucasians
B. S. Belgado PharmD, L. H. Cavallari PharmD, T. Langaee PhD, T. Okorochukwu, A. Sloan MSC and J. Johnson PharmD
Clin Pharmacol Ther 75: P95-P95; doi:10.1016/j.clpt.2003.11.362
Alpha-2B adrenergic receptor (ADRA2B) 301-303 deletion polymorphism and vascular desensitization in vivo
M. Muszkat MD, G. Sofowora MD, H. Xie MD, PhD, P. A. Harris PhD, A. J. Wood MD and C. Stein MD
Clin Pharmacol Ther 75: P95-P95; doi:10.1016/j.clpt.2003.11.363
Vitamin E formulation affects digoxin absorption by inhibiting P-glycoprotein (P-GP) in humans
L. Chan PharmD, L. M. Humma PharmD, C. A. Schriever PharmD, MS, L. A. Fahsingbauer BS, C. P. Dominguez and C. L. Baum MD, MS
Clin Pharmacol Ther 75: P95-P95; doi:10.1016/j.clpt.2003.11.364
Comparison of midazolam (MDZ) and simvastatin (SV) as cytochrome P450 (CYP) 3A probes during baseline (BAS), inhibition (INHIB), and induction (INDUC)
E. Chung PharmD, A. N. Nafziger MD, D. J. Kazierad PharmD and J. S. Bertino Jr PharmD
Clin Pharmacol Ther 75: P96-P96; doi:10.1016/j.clpt.2003.11.365
The effect of rifaximin on the pharmacokinetics of a single dose of ethinyl estradiol and norgestimate in healthy female volunteers
A. King MD, O. Marshall BS, M. Connolly PhD, A. Kamm PhD, H. Boxenbaum PhD, H. Kastrissios PhD and C. Trapnell MD
Clin Pharmacol Ther 75: P96-P96; doi:10.1016/j.clpt.2003.11.366
Effect of St. John's Wort on imatinib mesylate pharmacokinetics
R. F. Frye PhD, S. M. Fitzgerald BA, T. F. Lagattuta BS and M. J. Egorin MD
Clin Pharmacol Ther 75: P96-P96; doi:10.1016/j.clpt.2003.11.367
Assessment of ritonavir effects on hepatic and first-pass CYP3A activity and methadone disposition using noninvasive pupillometry
E. D. Kharasch MD, PhD and C. Hoffer CCRC
Clin Pharmacol Ther 75: P96-P96; doi:10.1016/j.clpt.2003.11.368
Mechanism-based modeling of the effects of ibutilide (IB) on ventricular repolarization in patients with atrial fibrillation (AF).
B. R. Overholser PharmD, J. E. Tisdale PharmD, B. L. Cariera PharmD and K. M. Sowinski PharmD
Clin Pharmacol Ther 75: P97-P97; doi:10.1016/j.clpt.2003.11.369
Population pharmacokinetic and pharmacodynamic model of CP-101,606 following a 72-hour infusion in acute ischemic stroke patients
T. J. Taylor MS, RPh, D. Mould PhD, P. Ravva MS, M. Krams MD, J. J. Weaver MS, T. Morse BS, M. M. Bednar MD and L. J. Benincosa PhD
Clin Pharmacol Ther 75: P97-P97; doi:10.1016/j.clpt.2003.11.370
Nonlinear mixed effects modeling of time dependencies in drug-free ECG data from healthy volunteers
P. Ravva MS, M. R. Gastonguay PhD, K. R. Sweeney PhD, M. A. Gibbs PhD, T. G. Tensfeldt MS and L. J. Benincosa PhD
Clin Pharmacol Ther 75: P97-P97; doi:10.1016/j.clpt.2003.11.371
Modeling of placebo drug effect using a population pharmacodynamic mixture model
B. E. Houk PhD and I. Nestorov Ph.D
Clin Pharmacol Ther 75: P97-P97; doi:10.1016/j.clpt.2003.11.372
Author index
Index to abstract authors
Clin Pharmacol Ther 75: P98-P105; doi:10.1016/S0009-9236(04)00024-4
